https://www.astrazeneca.com/ 2018-06-22T12:53:46.851+01:00 https://www.astrazeneca.com/2018-astrazeneca-start-up-science-competition.html 2018-05-24T11:52:20.654+01:00 https://www.astrazeneca.com/astrazeneca-joins-the-international-federation-to-recognise-world-diabetes-day.html 2017-11-14T09:29:25.767Z https://www.astrazeneca.com/ACC-2018.html 2018-03-08T11:27:06.105Z https://www.astrazeneca.com/az-suppliers.html 2017-12-14T14:45:52.198Z https://www.astrazeneca.com/az-suppliers/supplier-contact-information.html 2018-04-12T15:49:32.878+01:00 https://www.astrazeneca.com/Harnessing-the-code-of-life-to-develop-new-treatments.html 2017-07-06T14:55:22.204+01:00 https://www.astrazeneca.com/Harnessing-the-code-of-life-to-develop-new-treatments/sequencing-the-genome-the-cambridge-effect.html 2017-01-11T17:34:03.793Z https://www.astrazeneca.com/Harnessing-the-code-of-life-to-develop-new-treatments/protecting-patient-data.html 2017-01-11T17:34:45.438Z https://www.astrazeneca.com/patient-reported-outcomes.html 2018-02-21T10:10:23.788Z https://www.astrazeneca.com/patient-reported-outcomes/gastrointestinal.html 2017-07-06T15:13:11.984+01:00 https://www.astrazeneca.com/patient-reported-outcomes/cardiovascular.html 2018-02-21T11:04:33.833Z https://www.astrazeneca.com/patient-reported-outcomes/respiratory.html 2017-07-06T15:13:11.984+01:00 https://www.astrazeneca.com/patient-reported-outcomes/order-instrument.html 2017-07-06T13:51:55.943+01:00 https://www.astrazeneca.com/patient-reported-outcomes/faqs.html 2018-02-21T10:10:51.178Z https://www.astrazeneca.com/patient-reported-outcomes/contact-us.html 2017-07-06T14:59:29.634+01:00 https://www.astrazeneca.com/patient-reported-outcomes/confirmation.html 2016-10-03T11:40:27.637+01:00 https://www.astrazeneca.com/astrazeneca-exchange.html 2018-06-18T09:47:02.941+01:00 https://www.astrazeneca.com/astrazeneca-exchange/Gothenburg.html 2018-05-24T10:43:05.828+01:00 https://www.astrazeneca.com/astrazeneca-exchange/Gothenburg/about-astrazeneca-gothenburg-2016-event.html 2017-07-06T14:24:01.233+01:00 https://www.astrazeneca.com/astrazeneca-exchange/Gothenburg/about-the-astrazeneca-bioventurehub-a-catalyst-for-science-innovation.html 2017-07-06T14:24:01.226+01:00 https://www.astrazeneca.com/astrazeneca-exchange/Gothenburg/about-astrazeneca-gothenburg.html 2018-02-22T14:52:42.438Z https://www.astrazeneca.com/astrazeneca-exchange/Gothenburg/about-astrazeneca-gothenburg-2017-event.html 2018-02-22T14:51:27.139Z https://www.astrazeneca.com/astrazeneca-exchange/Cambridge.html 2017-07-06T14:24:01.230+01:00 https://www.astrazeneca.com/media-centre.html 2018-05-16T16:00:39.783+01:00 https://www.astrazeneca.com/media-centre/press-releases1/2009/MedImmune-Replies-to-FDA-Complete-Response-Letter-on-Motavizumab-24122009.html 2016-07-07T12:00:20.710+01:00 https://www.astrazeneca.com/media-centre/astrazeneca-q1-2018-financial-results.html 2018-05-18T10:22:25.986+01:00 https://www.astrazeneca.com/media-centre/press-releases.html 2018-04-27T11:04:58.169+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-eu-for-the-treatment-of-adults-with-hyperkalaemia-22032018.html 2018-04-02T23:04:18.205+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma-10012018.html 2018-01-10T15:07:51.640Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-12012018.html 2018-01-15T13:38:48.402Z https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-recieves-approval-in-japan-19012018.html 2018-01-18T22:11:19.282Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-receives-approval-in-japan-for-the-treatment-of-advanced-ovarian-cancer-19012018.html 2018-01-18T22:05:43.626Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-listed-as-one-of-the-worlds-top-100-most-sustainable-companies-and-recognised-for-its-three-fold-increase-in-renewable-energy-usage-23012018.html 2018-01-23T07:52:37.266Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-top-line-phase-iii-kronos-trial-results-for-pt010-triple-combination-therapy-in-chronic-obstructive-pulmonary-disease-26102018.html 2018-01-26T18:31:56.609Z https://www.astrazeneca.com/media-centre/press-releases/2018/full-year-2017-results.html 2018-02-02T08:08:45.295Z https://www.astrazeneca.com/media-centre/press-releases/2018/brilinta-significantly-reduces-cv-events-and-coronary-death-beyond-one-year-in-heart-attack-survivors-with-multi-vessel-disease-07022018.html 2018-02-07T07:08:35.088Z https://www.astrazeneca.com/media-centre/press-releases/2018/selumetinib-granted-orphan-drug-designation-by-the-us-fda-for-neurofibromatosis-type-1-15022018.html 2018-02-15T06:53:14.414Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer-180202018.html 2018-02-23T06:48:59.242Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-receives-positive-eu-chmp-opinion-in-platinum-sensitive-relapsed-ovarian-cancer-23022018.html 2018-02-23T12:25:13.406Z https://www.astrazeneca.com/media-centre/press-releases/2018/medimmune-to-create-stand-alone-company-for-early-stage-inflammation-and-autoimmunity-biologics-28022018.html 2018-02-28T06:28:49.957Z https://www.astrazeneca.com/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-forxiga-in-adults-with-type-1-diabetes-05032018.html 2018-03-05T06:27:47.333Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-aims-to-advance-clinical-practice-in-cv-risk-management-with-new-data-at-acc-2018-05032018.html 2018-03-05T06:25:25.526Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-mystic-trial-timeline-12032018.html 2018-03-12T08:11:11.943Z https://www.astrazeneca.com/media-centre/press-releases/2018/new-data-from-landmark-cvd-real-study-of-patients-with-type-2-diabetes-confirms-cv-benefits-associated-with-sglt-2-inhibitors-12032018.html 2018-03-12T07:00:40.061Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-03042018.html 2018-04-03T06:48:00.427+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-03042018.html 2018-04-03T06:45:00.103+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/astrazenecas-early-and-late-stage-oncology-portfolio-showcased-at-aacr-annual-meeting-and-elcc-04042018.html 2018-04-06T18:21:10.245+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/1st-line-tagrisso-demonstrates-sustained-benefit-post-progression-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-13042018.html 2018-04-13T14:52:55.714+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/updated-overall-survival-data-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr-16042018.html 2018-04-16T11:51:08.349+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-tagrisso-as-1st-line-treatment-for-EGFR-mutated-non-small-cell-lung-cancer.html 2018-04-19T16:41:53.280+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-non-small-cell-lung-cancer-24042018.html 2018-04-24T06:22:23.881+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/tagrisso-receives-positive-eu-chmp-opinion-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer27042018.html 2018-04-27T15:03:20.591+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer08052018.html 2018-05-08T11:17:45.404+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-and-luye-pharma-group-enter-agreement-for-rights-to-seroquel-and-seroquel-xr-in-the-uk-china-and-other-international-markets.html 2018-05-07T14:14:40.181+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-11052018.html 2018-05-11T07:06:22.118+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-is-advancing-clinical-practice-in-respiratory-medicine-with-new-data-at-the-american-thoracic-society-2018-international-congress.html 2018-05-16T06:46:23.318+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/new-england-journal-of-medicine-publishes-two-trials-for-symbicort-as-an-anti-inflammatory-reliever-therapy-as-needed-in-mild-asthma16052018.html 2018-05-17T14:37:29.771+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/q1-2018-results.html 2018-05-18T07:21:48.563+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/regulatory-submission-in-japan-for-forxiga-in-type-1-diabetes-21052018.html 2018-06-05T09:57:09.815+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html 2018-06-04T17:02:06.989+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-heads-to-2018-asco-annual-meeting-with-its-diversified-oncology-portfolio-and-next-generation-pipeline24052018.html 2018-05-24T22:37:17.047+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018.html 2018-05-25T00:55:11.430+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-30052018.html 2018-05-30T05:54:50.340+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/moxetumomab-pasudotox-pivotal-data-in-patients-with-previously-treated-hairy-cell-leukaemia-presented-at-the-2018-asco-meeting-04062018.html 2018-06-04T14:12:10.299+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-in-combination-with-abiraterone-delayed-disease-progression-in-metastatic-castration-resistant-prostate-cancer-04062018.html 2018-06-04T22:02:58.634+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/the-eu-approves-tagrisso-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-08062018.html 2018-06-11T14:00:30.120+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html 2018-06-12T06:22:15.675+01:00 https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-share-latest-data-from-an-industry-leading-portfolio-that-aims-to-advance-clinical-understanding-of-diabetes-and-cv-risk-management-at-ada-2018-19062018.html 2018-06-19T06:52:04.974+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-pieris-pharmaceuticals-collaborate-to-develop-and-commercialise-anticalin-based-inhaled-treatments-for-respiratory-diseases-03052017.html 2017-05-03T06:31:31.251+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-programme-opportunities-17012017.html 2017-01-26T14:47:40.196Z https://www.astrazeneca.com/media-centre/press-releases/2017/symbicort-granted-paediatric-exclusivity-in-the-us-26012017.html 2017-01-26T10:12:39.603Z https://www.astrazeneca.com/media-centre/press-releases/2017/full-year-and-q4-2016-results-02022017.html 2017-02-10T13:54:04.176Z https://www.astrazeneca.com/media-centre/press-releases/2017/Siliq-brodalumab-approved-by-the-US-FDA-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-160220170.html 2017-02-16T12:06:07.300Z https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-meets-primary-endpoint-in-phase-iii-trial-in-brca-mutated-metastatic-breast-cancer-17022017.html 2017-02-17T06:53:58.246Z https://www.astrazeneca.com/media-centre/press-releases/2017/updated-durvalumab-monotherapy-data-confirm-results-in-urothelial-bladder-cancer-17022017.html 2017-02-17T17:23:06.562Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-tersera-therapeutics-for-zoladex-in-the-us-and-canada-20022017.html 2017-03-21T10:34:17.144Z https://www.astrazeneca.com/media-centre/press-releases/2017/zs-9-sodium-zirconium-cyclosilicate-receives-positive-chmp-opinion-for-the-treatment-of-hyperkalaemia-24022017.html 2017-02-24T12:50:26.828Z https://www.astrazeneca.com/media-centre/press-releases/2017/fda-approves-once-daily-qtern-dapagliflozin-and-saxagliptin-tablets-for-adults-with-type-2-diabetes-240217.html 2017-02-28T06:40:45.511Z https://www.astrazeneca.com/media-centre/press-releases/2017/medimmune-and-sanofi-pasteur-form-alliance-to-develop-and-commercialise-potential-next-generation-respiratory-syncytial-virus-antibody-medi8897-030317.html 2017-03-03T06:57:12.544Z https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-phase-iii-solo-2-data-demonstrate-progression-free-survival-benefit-in-brca-mutated-ovarian-cancer-as-maintenance-therapy-14032017.html 2017-03-14T18:10:09.196Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-receives-complete-response-letter-from-us-fda-for-zs-sodium-zirconium-cyclosilicate-for-hyperkalaemia-17032017.html 2017-03-17T07:08:09.857Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-circassia-enter-strategic-collaboration-in-respiratory-disease-17032017.html 2017-03-17T07:28:05.690Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-s-cvd-real-study-shows-sglt-2-inhibitors-significant-reduced-death-and-hospitalisations-for-heart-failure-versus-other-type-2-diabetes-medicines-19032017.html 2017-03-20T06:20:19.010Z https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-approved-in-china-as-first-in-class-treatment-for-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer-27032017.html 2017-03-27T06:49:39.829+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-share-its-robust-early-science-in-oncology-with-the-medical-community-at-aacr-28032017.html 2017-03-28T06:21:24.217+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazenecas-potential-medicine-for-neuromyelitis-optica-spectrum-disorder-receives-orphan-designation-in-europe-29032017.html 2017-03-31T06:14:50.251+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-osimertinib-receives-us-fda-full-approval-31032017.html 2017-03-31T06:36:39.526+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-marks-a-key-milestone-with-the-topping-out-of-new-global-r-and-d-centre-and-hq-in-cambridge-uk-25042017.html 2017-04-25T13:46:29.260+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-receives-full-approval-in-the-eu-25042017.html 2017-04-25T13:36:16.314+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/q1-2017-results.html 2017-05-02T13:15:24.070+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazenecas-imfinzi-durvalumab-receives-us-fda-accelerated-approval-for-previously-treated-patients-with-advanced-bladder-cancer-01052017.html 2017-05-08T10:36:46.641+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-provides-update-on-stratos-1-phase-iii-trial-of-tralokinumab-in-severe-uncontrolled-asthma-100517.html 2017-05-10T12:40:11.286+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/imfinzi-significantly-reduces-the-risk-of-disease-worsening-or-death-in-the-phase-iii-pacific-trial-for-stage-iii-unresectable-lung-cancer-12052017.html 2017-08-17T10:46:09.430+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-scientific-advancements-from-growing-respiratory-portfolio-at-the-american-thoracic-society-conference-2017-18052017.html 2017-05-18T08:15:49.656+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/brodalumab-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-moderate-to-severe-plaque-psoriasis-19052017.html 2017-05-19T13:57:23.937+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-recordati-for-seloken-in-europe-22052017.html 2017-05-22T07:36:49.962+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/phase-iii-zonda-trial-for-benralizumab-shows-ability-to-reduce-oral-steroid-use-in-severe-asthma-patients-22052017.html 2017-05-22T19:44:40.502+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html 2017-05-23T07:05:03.053+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-delivers-new-data-on-expanding-portfolio-of-cancer-medicines-at-2017-american-society-of-clinical-oncology-(asco)-annual-meeting-26052017.html 2017-07-06T13:56:48.548+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-appoints-professor-nazneen-rahman-to-its-board-of-directors-and-science-committee-31052017.html 2017-05-31T06:29:38.254+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-significantly-reduces-the-risk-of-disease-worsening-or-death-in-patients-with-BRCA-mutated-metastatic-breast-cancer-04062017.html 2017-06-04T21:36:26.317+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-grunenthal-to-divest-rights-to-migraine-treatment-zomig-07062017.html 2017-06-07T13:03:13.932+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-scientific-advances-in-cardiovascular-and-metabolic-diseases-at-2017-ada-scientific-sessions-08062017.html 2017-06-08T06:36:08.741+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-new-data-underpinning-safety-profile-and-real-world-cv-outcomes-of-farxiga-at-ada-2017-12062017.html 2017-06-12T06:29:08.925+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-fulvestrant-receives-positive-chmp-opinion-for-use-in-1st-line-hormone-receptor-positive-advanced-breast-cancer-23062017.html 2017-06-23T13:18:52.189+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/kyntheum-approved-in-the-eu-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis-20072017.html 2017-07-20T17:08:05.358+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-eu-approval-as-first-line-therapy-for-advanced-breast-cancer-26072017.html 2017-07-26T17:43:28.704+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/h1-2017-results.html 2017-08-01T15:03:37.641+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-merck-establish-strategic-oncology-collaboration-27072017.html 2017-07-27T08:11:01.617+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html 2017-07-27T06:49:00.525+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-significantly-improves-progression-free-survival-in-the-phase-iii-flaura-trial-for-lung-cancer-27072017.html 2017-07-27T08:16:13.408+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/imfinzi-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-locally-advanced-unresectable-non-small-cell-lung-cancer-31072017.html 2017-08-02T14:01:10.221+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma-01082017.html 2017-08-01T07:02:24.592+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-acalabrutinib-and-grants-priority-review-02082017.html 2017-08-02T07:04:22.752+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-receives-additional-and-broad-approval-in-the-us-for-ovarian-cancer-17082017.html 2017-08-17T20:38:25.677+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/extended-treatment-with-brilinta-reduces-risk-of-cardiovascular-death-by-29-percent-in-patients-with-history-of-heart-attack-24082017.html 2017-08-24T07:08:34.500+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-takeda-establish-collaboration-to-develop-and-commercialise-medi1341-for-parkinsons-disease-25082017.html 2017-08-27T21:03:16.984+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-breast-cancer.html 2017-08-27T21:14:25.567+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-highlights-latest-advances-in-lung-cancer-at-the-esmo-2017-congress-31082017.html 2017-08-31T09:14:42.645+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-data-on-next-generation-of-biologics-at-european-respiratory-society-international-congress-04092017.html 2017-09-04T06:35:03.895+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients-with-severe-uncontrolled-asthma-06092017.html 2017-09-06T21:46:07.674+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/duaklir-significantly-improves-lung-function-in-copd-patients-07092017.html 2017-09-07T06:54:56.617+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/celgene-and-astrazeneca-provide-update-on-the-fusion-clinical-trial-programme-07092017.html 2017-09-07T12:58:18.645+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-tagrisso-shows-potential-as-a-new-standard-of-care-in-1st-line-egfr-mutated-lung-cancer-at-esmo-2017-congress-08092017.html 2017-09-08T22:45:09.126+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html 2017-09-09T15:45:23.444+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-new-results-identifying-severe-asthma-patients-who-would-benefit-most-from-benralizumab-11092017.html 2017-09-11T06:46:34.971+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-aspen-enter-agreement-for-remaining-rights-to-anaesthetics-medicines14092017.html 2017-09-14T06:13:15.761+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-demonstrates-favourable-cardiovascular-cv-safety-profile-and-fewer-cv-events-in-patients-with-type-2-diabetes-at-wide-range-of-cv-risk14092017.html 2017-09-14T17:27:16.660+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/bevespi-aerosphere-demonstrates-statistically-significant-improvement-in-lung-function-in-patients-with-copd-25092017.html 2017-09-25T07:00:53.117+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/the-european-medicines-agency-accepts-marketing-authorisation-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-09102017.html 2017-10-09T06:20:06.911+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-granted-breakthrough-therapy-designation-by-us-fda-for-the-1st-line-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-09102017.html 2017-10-09T06:40:07.849+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-shares-its-comprehensive-scientific-approach-at-the-world-conference-on-lung-cancer-2017-16102017.html 2017-10-16T06:53:58.209+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-171017.html 2017-10-17T06:35:56.834+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-lynparza-in-metastatic-breast-cancer-and-grants-priority-review-18102017.html 2017-10-18T06:56:14.471+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes-231017.html 2017-10-23T06:21:09.010+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-msd-rapidly-advance-lynparza-in-japan-with-a-second-regulatory-submission-231017.html 2017-10-23T07:10:33.578+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html 2017-10-31T17:25:53.479Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-incyte-enter-clinical-trial-collaboration-in-early-lung-cancer-31102017.html 2017-10-31T07:28:04.679Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-provides-update-on-tralokinumab-phase-iii-programme-in-severe-uncontrolled-asthma-01112017.html 2017-11-01T06:43:33.635Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-shares-scientific-updates-from-its-extensive-cardiovascular-renal-and-metabolic-diseases-cvmd-portfolio-at-aha-2017-08112017.html 2017-11-07T19:50:30.563Z https://www.astrazeneca.com/media-centre/press-releases/2017/year-to-date-and-q3-2017-results.html 2017-11-13T13:07:46.608Z https://www.astrazeneca.com/media-centre/press-releases/2017/benralizumab-receives-positive-eu-chmp-opinion-for-severe-uncontrolled-eosinophilic-asthma-10112017.html 2018-04-30T09:42:21.740+01:00 https://www.astrazeneca.com/media-centre/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html 2017-11-14T23:14:46.133Z https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-for-the-treatment-of-advanced-breast-cancer-in-combination-with-abemaciclib-15112017.html 2017-11-15T06:27:52.979Z https://www.astrazeneca.com/media-centre/press-releases/2017/the-european-medicines-agency-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-24112017.html 2017-11-28T06:06:50.359Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-chinese-future-industry-investment-fund-establish-joint-venture-to-develop-new-medicines-in-china-27112017.html 2017-11-27T06:50:34.415Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-makes-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-in-japan-27112017.html 2017-11-27T06:31:12.310Z https://www.astrazeneca.com/media-centre/press-releases/2017/tudorza-reduces-exacerbations-and-demonstrates-cardiovascular-safety-in-copd-patients-041217.html 2017-12-03T21:47:29.824Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-highlight-its-commitment-to-blood-cancers-at-the-2017-american-society-of-hematology-annual-meeting-06122017.html 2017-12-06T06:11:19.215Z https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-18122017.html 2017-12-18T07:12:49.366Z https://www.astrazeneca.com/media-centre/press-releases/2016.html 2016-11-22T17:01:57.829Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-head-and-neck-cancer-trials-27102016.html 2017-01-13T15:03:23.012Z https://www.astrazeneca.com/media-centre/press-releases/2016/q3-2016-results.html 2017-01-13T15:14:03.843Z https://www.astrazeneca.com/media-centre/press-releases/2016/fda-accepts-for-review-new-drug-application-for-sodium-zirconium-18102016.html 2017-01-13T15:14:20.554Z https://www.astrazeneca.com/media-centre/press-releases/2016/lynparza-phase-iii-solo-2-trial-shows-significant-progression-free-survival-benefit-261020161.html 2017-01-13T15:14:36.328Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-acquisition-of-takedas-respiratory-business.html 2017-01-13T15:14:49.529Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin-diseases-01072016.html 2017-01-13T15:15:02.939Z https://www.astrazeneca.com/media-centre/press-releases/2016/Tagrisso-met-primary-endpoint-in-phase-III-2nd-line-lung-cancer-trial-18072016.html 2017-01-13T15:15:16.287Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-receives-approval-in-the-EU-for-Qtern-saxagliptin-and-dapagliflozin-for-treatment-of-Type-2-diabetes.html 2017-01-13T15:15:29.146Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZenecas-antibiotic-Zavicefta-met-primary-endpoints-in-Phase-III-trial-for-treatment-of-hospital-acquired-pneumonia-21072016.html 2017-01-13T15:15:44.953Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-files-first-clinical-trial-application-in-Moderna-messenger-RNA-collaboration-26072016.html 2017-01-13T15:15:59.540Z https://www.astrazeneca.com/media-centre/press-releases/2016/h1-2016-results.html 2017-01-13T15:16:13.209Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-provides-update-on-Phase-III-trial-of-Selumetinib-in-non-small-cell-lung-cancer-09082016.html 2017-01-13T15:16:29.002Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-and-lilly-receive-fda-fast-track-designation-for-azd3293-as-potential-treatment-for-early-alzheimers-disease-22082016.html 2017-01-13T15:16:44.473Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-to-sell-small-molecule-antibiotics-business-to-Pfizer-24082016.html 2017-01-13T15:17:01.801Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-to-present-new-data-highlighting-its-growing-respiratory-portfolio-ERS-30082016.html 2017-01-13T15:17:24.404Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-completes-commercialisation-agreement-with-Aspen-for-anaesthetics-portfolio-01092016.html 2017-01-13T15:17:58.782Z https://www.astrazeneca.com/media-centre/press-releases/2016/benralizumub-phase-III-trials-show-positive-results-in-severe-asthma-05092016.html 2017-01-13T15:18:13.339Z https://www.astrazeneca.com/media-centre/press-releases/2016/pepfar-and-astrazeneca-launch-partnership-across-hiv-and-hypertension-services-in-africa-080920161.html 2017-01-13T15:18:27.625Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-two-new-phase-IIIb-trials-for-Forxiga-in-chronic-kidney-disease-and-chronic-heart-failure-120920161.html 2017-01-13T15:18:42.470Z https://www.astrazeneca.com/media-centre/press-releases/2016/phase-III-combination-trial-of-bydureon-and-forxiga-shows-significant-benefits-in-patients-with-type-2-diabetes-1609201611.html 2017-01-13T15:18:56.662Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-update-on-cediranib-eu-marketing-authorisation-application-21092016.html 2017-01-13T15:19:11.904Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-presents-new-data-on-Faslodex-in-breast-cancer-and-provides-immuno-oncology-update-at-ESMO-2016-congress-30092016.html 2017-01-13T15:19:30.729Z https://www.astrazeneca.com/media-centre/press-releases/2016/medimmune-out-licenses-potential-medicine-for-inflammatory-diseases-to-allergan-03102016.html 2017-01-13T15:19:54.093Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-results-from-the-brilinta-euclid-trial-in-patients-with-peripheral-artery-disease-04102016.html 2017-01-13T15:20:17.191Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-agreement-with-aralez-for-beta-blocker-medicine-in-the-us-04102016.html 2017-01-13T15:20:38.108Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-agreement-with-cilag-gmbh-international-to-divest-rights-to-rhinocort-aqua-outside-the-us-071020161.html 2017-01-13T15:20:56.394Z https://www.astrazeneca.com/media-centre/press-releases/2016/MedImmune-completes-out-licensing-agreement-with-Allergan-for-MEDI2070-17112016.html 2017-01-13T15:21:12.026Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Moderna-Therapeutics-announce-new-collaboration-to-co-develop-and-co-commercialise-immuno-oncology-mRNA-therapeutics-11012016.html 2017-01-13T15:21:28.239Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-and-incyte-announce-new-lung-cancer-clinical-trial-collaboration-11012016.html 2017-01-13T15:22:36.102Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-partners-with-peers-and-academia-to-establish-translational-research-fund.html 2017-01-13T15:22:52.687Z https://www.astrazeneca.com/media-centre/press-releases/2016/Lynparza-Olaparib-granted-Breakthrough-Therapy-Designation-by-US-FDA-for-treatment-of-BRCA1-2-or-ATM-gene-mutated-metastatic-Castration-Resistant-Prostate-Cancer-28012016.html 2017-01-13T15:23:10.653Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-transaction-for-majority-equity-stake-investment-in-acerta-pharma-01022016.html 2017-01-13T15:23:29.237Z https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-osimertinib-approved-in-eu-as-first-in-class-treatment-for-lung-cancer-03022016.html 2017-01-13T15:23:48.978Z https://www.astrazeneca.com/media-centre/press-releases/2016/full-year-and-q4-2015-results-04022016.html 2017-01-13T15:24:10.826Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Medimmune-enter-consortium-to-deliver-new-treatments-for-chronic-kidney-disease-11022016.html 2017-01-13T15:24:26.184Z https://www.astrazeneca.com/media-centre/press-releases/2016/Durvalumab-granted-Breakthrough-Therapy-designation-by-US-FDA-for-treatment-of-patients-with-PD-L1-positive-urothelial-bladder-cancer-17022016.html 2017-01-13T15:24:43.419Z https://www.astrazeneca.com/media-centre/press-releases/2016/zurampic-lesinurad-approved-in-the-european-union-for-patients-with-gout-19022016.html 2017-01-13T15:25:03.001Z https://www.astrazeneca.com/media-centre/press-releases/2016/Brilique-ticagrelor-approved-in-EU-for-extended-treatment-of-patients-with-history-of-heart-attack-19022016.html 2017-01-13T15:25:18.277Z https://www.astrazeneca.com/media-centre/press-releases/2016/acalabrutinib-recommended-for-orphan-drug-designation-in-europe-for-three-indications-25022016.html 2017-01-13T15:25:35.697Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-enters-licensing-agreement-with-China-Medical-System-Holdings-for-hypertension-medicine-29022016.html 2017-01-13T15:25:51.337Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html 2017-01-13T15:26:19.482Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-into-agreement-with-prostrakan-for-rights-to-moventig-in-europe-03012016.html 2017-01-13T15:26:37.699Z https://www.astrazeneca.com/media-centre/press-releases/2016/Medimmune-receives-fast-track-designation-in-the-US-for-MEDI8852-for-treatment-of-patients-hospitalised-with-influenza-A-07032016.html 2017-01-13T15:26:54.499Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazenecas-potential-medicine-for-neuromyelitis-optica-receives-fda-orphan-drug-designation-09032016.html 2017-01-13T15:27:11.189Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-results-from-the-brilinta-socrates-trial-in-stroke-23032016.html 2017-01-13T15:27:38.302Z https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-approved-in-japan-for-patients-with-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer-29032016.html 2017-01-13T15:28:08.763Z https://www.astrazeneca.com/media-centre/press-releases/2016/brilinta-preferred-over-clopidogrel-in-updated-american-college-of-cardiology-and-american-heart-association-guideline-in-acute-coronary-syndrome-31032016.html 2017-01-13T15:28:33.767Z https://www.astrazeneca.com/media-centre/press-releases/2016/pandemic-influenza-vaccine-receives-positive-chmp-opinion-01042016.html 2017-01-13T15:29:19.477Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-to-showcase-clinical-and-scientific-leadership-in-lung-cancer-at-ELCC-2016-06042016.html 2017-01-13T15:29:36.560Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Eli-Lilly-and-company-announce-continuation-of-pivotal-clinical-trial-for-people-with-early-alzheimers-disease-08042016.html 2017-01-13T15:29:54.788Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-showcases-breadth-of-oncology-portfolio-at-aacr-2016-annual-meeting-14042016.html 2017-01-13T15:30:14.856Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-launches-integrated-genomics-approach-to-transform-drug-discovery-and-development-22042016.html 2017-01-13T15:30:42.708Z https://www.astrazeneca.com/media-centre/press-releases/2016/bevespi-aerosphere-approved-by-the-us-fda-for-patients-with-copd-25042016.html 2017-01-13T15:30:58.344Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-into-us-licensing-agreement-with-ironwood-pharmaceuticals-for-lesinurad-26042016.html 2017-01-13T15:31:18.061Z https://www.astrazeneca.com/media-centre/press-releases/2016/q1-2016-results.html 2017-01-13T15:31:42.691Z https://www.astrazeneca.com/media-centre/press-releases/2016/positive-chmp-opinion-for-caz-avi-in-the-eu-for-serious-bacterial-infections-29042016.html 2017-01-13T15:32:11.137Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-divestment-of-imdur-to-china-medical-system-holdings-03052016.html 2017-01-13T15:32:31.586Z https://www.astrazeneca.com/media-centre/press-releases/2016/selumetinib-granted-orphan-drug-designation-in-the-US-for-adjuvant-treatment-of-differentiated-thyroid-cancer-12052016.html 2017-01-13T15:33:06.526Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-to-highlight-the-breadth-of-its-respiratory-medicines-at-american-thoracic-society-2016-international-conference-12052016.html 2017-01-13T15:33:29.893Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-positive-results-from-benralizumab-phase-iii-programme-in-severe-asthma-17052016.html 2017-01-13T15:34:36.280Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-top-line-results-from-lynparza-gold-trial-in-advanced-gastric-cancer-1805206.html 2017-01-13T15:34:52.384Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-highlights-continued-progress-of-oncology-pipeline-at-asco-2016-19052016.html 2017-01-13T15:35:08.458Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazenecas-faslodex-met-primary-endpoint-in-first-line-treatment-of-advanced-breast-cancer.html 2017-01-13T15:35:26.436Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-receives-complete-response-letter-from-us-fda-for-sodium-zirconium-cyclosilicate-zs-9-for-oral-suspension-for-treatment-of-hyperkalaemia-27052016.html 2017-01-13T15:35:44.564Z https://www.astrazeneca.com/media-centre/press-releases/2016/positive-chmp-opinion-in-eu-for-saxa-dapa-for-adults-with-type-2-diabetes-27052016.html 2017-01-13T15:36:04.452Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-licenses-Zurampic-to-Grunenthal-GmbH-in-Europe-and-Latin-America-02062016.html 2017-01-13T15:36:20.308Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-us-licensing-agreement-with-ironwood-pharmaceuticals-for-lesinurad-03062016.html 2017-01-13T15:36:36.736Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Foundation-Medicine-enter-strategic-collaboration-for-Lynparza-companion-diagnostic-assay-04062016.html 2017-01-13T15:37:00.298Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-commercialisation-agreement-with-aspen-for-anaesthetic-medicines-portfolio-08062016.html 2017-01-13T15:38:02.861Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-update-on-flumist-quadrivalent-vaccine-in-the-us-for-the-2016-17-influenza-season-23062016.html 2017-01-13T15:38:26.811Z https://www.astrazeneca.com/media-centre/press-releases/2016/New-antibiotic-Zavicefta-approved-in-the-European-Union-for-patients-with-serious-bacterial-infections-28062016.html 2017-01-13T15:38:43.365Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-head-and-neck-cancer-trials-resume-new-patient-enrolment-as-fda-lifts-partial-clinical-hold-22112016.html 2017-01-13T15:39:01.542Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-takes-latest-scientific-advances-in-oncology-to-major-us-and-european-congresses29112016.html 2017-01-13T15:39:36.952Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-agreement-with-cilag-gmbh-international-for-rights-to-rhinocort-aqua-outside-the-us-05122016.html 2017-01-13T15:39:57.631Z https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-demonstrates-superiority-over-chemotherapy-in-egfr-t790m-mutation-positive-non-small-cell-lung-cancer-06122016.html 2017-07-06T13:56:48.480+01:00 https://www.astrazeneca.com/media-centre/press-releases/2016/Astrazeneca-and-Lilly-to-develop-second-potentially-disease-modifying-treatment-for-alzheimers-disease-09122016.html 2017-01-13T15:40:35.984Z https://www.astrazeneca.com/media-centre/press-releases/2016/US-FDA-accepts-first-biologics-license-application-for-AstraZenecas-durvalumab-in-bladder-cancer-09122016.html 2017-01-13T15:40:58.617Z https://www.astrazeneca.com/media-centre/press-releases/2015.html 2016-11-22T17:01:47.383Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-archaeological-dig-cambridge-biomedical-campus-11062015.html 2017-01-13T09:05:39.037Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-pam-cheng-executive-vice-president-operations-16062015.html 2017-01-13T09:49:08.016Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-oncology-research-european-cancer-congress-2015-24092015.html 2017-01-19T10:43:01.994Z https://www.astrazeneca.com/media-centre/press-releases/2015/real-world-data-saxagliptin-sitagliptin-heart-failure-risk-08062015.html 2017-01-19T10:43:31.725Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-type-2-diabetes-triple-therapy-treatment-data-06062015.html 2017-01-19T10:44:27.126Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-diabetes-data-american-diabetes-association-scientific-sessions-03062015.html 2017-01-19T11:34:39.484Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-immuno-oncology-combinations-development-programme-asco-2015-02062015.html 2017-01-19T11:35:34.688Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-medimmune-positive-immuno-oncology-combination-data-asco-30052015.html 2017-01-19T11:37:13.527Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-lilly-immuno-oncology-clinical-trial-solid-tumours-29052015.html 2017-01-19T11:37:27.304Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-brodalumab-development-programme-psoriasis-arthritis-22052015.html 2017-01-19T11:38:02.777Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-biologics-manufacturing-sodertalje-sweden-18052015.html 2017-01-19T11:38:29.617Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-immuno-oncology-pipeline-combination-treatments-asco-2015-13052015.html 2017-01-19T11:38:42.906Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-abbott-companion-diagnostic-tests-tralokinumab-severe-asthma-13052015.html 2017-01-19T11:39:52.922Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-montreal-heart-institute-cardiovascular-diabetes-genetic-screening-13052015.html 2017-01-19T11:40:08.315Z https://www.astrazeneca.com/media-centre/press-releases/2015/us-fda-priority-review-brilinta-heart-attack-history-patients-29042015.html 2017-01-19T11:40:29.472Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-first-quarter-results-2015-24042015.html 2017-07-06T13:56:48.489+01:00 https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-celgene-corporation-immuno-oncology-collaboration-blood-cancers-24042015.html 2017-01-19T11:41:26.506Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-innate-pharma-global-collaboration-immuno-oncology-24042015.html 2017-01-19T11:42:08.263Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-non-small-cell-lung-cancer-medicine-data-european-lung-cancer-congress-17042015.html 2017-01-19T11:42:24.763Z https://www.astrazeneca.com/media-centre/press-releases/2015/selumetinib-orphan-drug-designation-us-fda-uveal-melanoma-treatment-17042015.html 2017-01-19T11:42:40.376Z https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-immunocore-immuno-oncology-combination-trials-melanoma-16042015.html 2017-01-19T11:42:53.108Z https://www.astrazeneca.com/media-centre/press-releases/2015/tremelimumab-orphan-drug-designation-us-fda-malignant-mesothelioma-treatment-15042015.html 2017-01-19T11:43:11.540Z https://www.astrazeneca.com/media-centre/press-releases/2015/fda-advisory-committee-reviews-saxagliptin-type-2-diabetes-14042015.html 2017-01-19T11:43:33.896Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-patientslikeme-research-oncology-diabetes-lupus-respiratory-disease-13042015.html 2017-01-19T11:43:49.642Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-oncology-science-american-association-cancer-research-annual-meeting-2015-13042015.html 2017-01-19T11:44:15.668Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-genomics-england-consortium-26032015.html 2017-01-19T11:44:52.461Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-harvard-stem-cell-institute-diabetes-25032015.html 2017-01-19T11:45:24.912Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-daiichi-sankyo-commercialise-movantik-19032015.html 2017-01-19T11:45:48.344Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-pt003-results-chronic-obstructive-pulmonary-disease-18032015.html 2017-01-19T11:46:12.077Z https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-study-brilinta-long-term-treatment-reduces-cardiovascular-thrombotic-events-14032015.html 2017-01-19T11:46:25.487Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-us-fda-endocrinologic-metabolic-drugs-advisory-committee-04032015.html 2017-01-19T11:52:16.037Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-actavis-respiratory-portfolio-chronic-obstructive-pulmonary-disease-03032015.html 2017-01-19T11:52:46.810Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-board-annual-general-meeting-17022015.html 2017-01-19T11:53:07.376Z https://www.astrazeneca.com/media-centre/press-releases/2015/us-district-court-decision-pulmicort-respulses-patent-litigation-13022015.html 2017-01-19T11:53:24.067Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-actavis-aclidinium-respiratory-franchise-05022015.html 2017-01-19T11:53:38.677Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-fourth-quarter-full-year-results-2014-05022015.html 2017-07-06T13:56:48.517+01:00 https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-research-development-centre-corporate-headquarters-cambridge-uk-04022015.html 2017-01-19T11:54:58.324Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-crispr-technology-genome-editing-29012015.html 2017-01-19T11:55:22.492Z https://www.astrazeneca.com/media-centre/press-releases/2015/lesinurad-gout-treatment-european-medicines-agency-22012015.html 2017-01-19T11:55:49.969Z https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-study-brilinta-reduction-cardiovascular-thrombotic-events-14012015.html 2017-01-19T11:56:10.790Z https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-omnis-pharmaceuticals-oncolytic-viruses-immuno-oncology-12012015.html 2017-01-19T12:01:35.191Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-daiichi-sankyo-flumist-influenza-vaccine-02092015.html 2017-01-19T12:02:00.615Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-valeant-pharmaceuticals-brodalumab-dermatology-psoriasis-01092015.html 2017-01-19T12:02:18.211Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-peregrine-pharmaceuticals-immuno-oncology-combination-clinical-trial-24082015.html 2017-01-19T12:02:34.719Z https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-mirati-therapeutics-immuno-oncology-combination-lung-cancer-05082015.html 2017-01-19T12:03:00.723Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-heptares-therapeutics-immuno-oncology-treatments-06082015.html 2017-01-19T12:59:13.646Z https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-inovio-pharmaceuticals-cancer-vaccine-10082015.html 2017-01-19T13:09:37.059Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-isis-pharmaceuticals-antisense-drugs-cardiovascular-metabolic-renal-diseases-03082015.html 2017-01-19T13:10:23.457Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-genzyme-rare-disease-medicine-caprelsa-27072015.html 2017-01-19T13:10:50.110Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-tillotts-pharma-entocort-gastroenterology-medicine-17072015.html 2017-01-19T13:12:00.175Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-kyowa-hakko-kirin-benralizumab-asthma-chronic-obstructive-pulmonary-disease-16072015.html 2017-01-19T13:14:31.965Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-tillotts-pharma-entocort-gastroenterology-09072015.html 2017-01-19T13:15:20.976Z https://www.astrazeneca.com/media-centre/press-releases/2015/iressa-fda-approved-non-small-cell-lung-cancer-treatment-13072015.html 2017-01-19T13:15:47.575Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-selumetinib-uveal-melanoma-oncology-22072015.html 2017-01-19T13:16:27.331Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-h1-results-2015-30072015.html 2017-07-06T13:56:48.500+01:00 https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-dr-sean-bohen-chief-medical-officer-24082015.html 2017-01-19T13:17:24.828Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-cardiovascular-events-prevention-esc-congress-2015-29082015.html 2017-01-19T13:19:11.226Z https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-brilinta-treatment-following-heart-attack-31082015.html 2017-01-19T13:19:35.647Z https://www.astrazeneca.com/media-centre/press-releases/2015/antibiotic-medicine-caz-avi-complicated-urinary-tract-infections-02092015.html 2017-01-19T13:20:10.590Z https://www.astrazeneca.com/media-centre/press-releases/2015/us-fda-approves-brilinta-long-term-use-heart-attack-history-patients-03092015.html 2017-01-19T13:20:51.138Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-lung-cancer-portfolio-world-conference-lung-cancer-2015-04092015.html 2017-01-19T13:22:24.147Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-manchester-clinical-oncology-bioinformatics-collaboration-08092015.html 2017-01-19T13:22:47.480Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-biologics-manufacturing-boulder-colorado-11092015.html 2017-01-19T13:23:13.157Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-diabetes-data-pre-clinical-research-easd-2015-11092015.html 2017-01-19T13:23:32.253Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-respiratory-disease-data-european-respiratory-society-international-congress-2015-22092015.html 2017-01-19T13:23:52.535Z https://www.astrazeneca.com/media-centre/press-releases/2015/new-england-journal-medicine-brodalumab-ustekinumab-psoriasis-30092015.html 2017-01-19T13:24:13.500Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-orca-pharmaceuticals-rory-inhibitors-auto-immune-diseases-treatment-25022015.html 2017-01-19T13:24:48.633Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-cambridge-judge-business-school-biotech-start-ups-03032015.html 2017-01-19T13:25:19.381Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-singapore-research-organisations-heart-failure-11032015.html 2017-01-19T13:26:20.894Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-scientific-review-board-clinical-trial-data-transparency-19032015.html 2017-01-19T13:26:45.840Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-bina-genomic-management-solution-21042015.html 2017-01-19T13:31:05.182Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-mene-pangalos-fellowship-academy-medical-sciences-11052015.html 2017-01-19T13:31:32.478Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-michigan-chronic-kidney-disease-treatments-17062015.html 2017-01-19T13:32:23.490Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-inserm-type-2-diabetes-chronic-kidney-disease-studies-17062015.html 2017-01-19T13:33:59.621Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-cambridge-phd-clinical-research-scholarships-30062015.html 2017-01-19T13:34:18.071Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-crowd-sourcing-challenge-combination-therapies-cancer-22092015.html 2017-01-19T13:34:55.405Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-receives-complete-response-letter-from-us-16102015.html 2017-01-19T13:35:22.674Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-opens-new-manufacturing-facility-to-support-continued20102015.html 2017-01-19T13:35:41.486Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-and-lilly-expand-immuno-oncology-research-collaborat-22102015.html 2017-01-19T13:35:58.965Z https://www.astrazeneca.com/media-centre/press-releases/2015/-fda-advisory-committee-recommends-the-approval-of-lesinurad-for-gout-patients-23102015.html 2017-01-19T13:36:22.677Z https://www.astrazeneca.com/media-centre/press-releases/2015/Year-To-Date-and-Q3-2015-Results-05112015.html 2017-07-06T13:56:48.514+01:00 https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-strengthens-Cardiovascular-and-Metabolic-disease-portfolio-with-acquisition-of-ZS-Pharma-06112015.html 2017-01-19T13:37:04.941Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-presents-positive-new-data-on-anifrolumab-in-lupus-at-American-College-of-Rheumatology-Annual-Scientific-Meeting-10112015.html 2017-01-19T13:37:22.873Z https://www.astrazeneca.com/media-centre/press-releases/2015/TAGRISSO-AZD9291-approved-by-the-US-FDA-for-patients-with-EGFR-T790M-mutation-positive-metastatic-non-small-cell-lung-cancer-13112015.html 2017-01-13T09:57:23.049Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-expands-technological-investment-in-new-Cambridge-lead-discovery-centre-20112015.html 2018-03-05T09:21:00.970Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-and-Sanofi-exchange-over-200000-chemical-compounds-20112015.html 2017-01-13T09:04:50.926Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-enters-into-agreement-with-Perrigo-for-rights-to-Entocort-in-the-US.html 2017-01-13T09:21:22.408Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-and-Voluntis-to-test-companion-mobile-app-in-ovarian-cancer-studies-07122015.html 2017-01-13T09:05:09.155Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-stand-alone-company-small-molecule-early-stage-antibiotic-research-development-26022015.html 2017-01-19T13:38:26.579Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-presents-positive-pooled-analysis-demonstrating-the-effect-of-dapagliflozin-on-albuminuria-in-hypertensive-patients-with-type-2-diabetes-17092015.html 2017-01-13T09:50:10.100Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-announces-new-tolerability-long-term-efficacy-and-real-world-adherence-data-for-exenatide-once-weekly-in-patients-with-type-2-diabetes-15092015.html 2017-01-13T09:05:25.978Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-to-harness-power-of-the-Secretome-and-develop-next-generation-biologics-11122015.html 2017-07-06T13:56:48.502+01:00 https://www.astrazeneca.com/media-centre/press-releases/2015/Discussions-with-Acerta-Pharma-BV-14122015.html 2017-01-17T15:40:33.420Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-completes-agreement-with-Perrigo-for-rights-to-Entocort-in-the-US-15122015.html 2017-01-13T09:16:15.568Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-continues-strategic-investment-in-China-to-accelerate-delivery-of-innovative-biologics-and-targeted-medicines-16122015.html 2017-01-13T09:16:30.429Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-to-strengthen-therapy-area-franchise-through-acquisition-of-Takedas-respiratory-business-16122015.html 2017-01-13T09:52:49.545Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-enhances-long-term-growth-through-Oncology-investment-in-Acerta-Pharma.html 2017-01-13T09:21:02.005Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-completes-acquisition-of-ZS-Pharma-17122015.html 2017-01-13T09:15:58.977Z https://www.astrazeneca.com/media-centre/press-releases/2015/Durvalumab-ATLANTIC-trial-supports-clinical-activity-and-AstraZenecas-overall-immuno-oncology-strategy.html 2017-01-13T09:58:04.789Z https://www.astrazeneca.com/media-centre/press-releases/2015/CHMP-issues-positive-opinion-on-lesinurad-for-Gout18122015.html 2017-01-13T09:54:12.735Z https://www.astrazeneca.com/media-centre/press-releases/2015/tagrisso-osimertinib--receives-positive-chmp-opinion-18122015.html 2017-01-13T09:57:07.784Z https://www.astrazeneca.com/media-centre/press-releases/2015/BRILIQUE-ticagrelor-receives-positive-European-Union-CHMP-opinion-for-extended-treatment-18122015.html 2017-01-13T09:53:50.546Z https://www.astrazeneca.com/media-centre/press-releases/2015/ZURAMPIC-lesinurad-approved-by-US-FDA-for-patients-with-gout-22122015.html 2017-01-13T09:55:30.336Z https://www.astrazeneca.com/media-centre/press-releases/2014.html 2016-11-22T17:01:35.567Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-immunocore-immunotherapy-novel-cancer-therapies-08012014.html 2017-01-18T17:21:54.831Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-bristol-myers-squibb-farxiga-us-fda-approval-08012014.html 2017-01-19T11:29:29.731Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-farxiga-treatment-type-2-diabetes-patients-13012014.html 2017-01-11T19:46:24.742Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazenca-scientific-leadership-growth-jp-morgan-healthcare-conference-14012014.html 2017-01-19T13:09:53.658Z https://www.astrazeneca.com/media-centre/press-releases/2014/xigduo-approved-european-union-type-2-diabetes-21012014.html 2017-01-19T13:55:44.186Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-aquisition-bristol-myers-squibb-global-diabetes-alliance-03022014.html 2017-01-19T12:06:15.929Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-fourth-quarter-full-year-results-2013-06022014.html 2017-07-06T13:56:48.481+01:00 https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-myalept-lepti-deficiency-treatment-25022014.html 2017-01-19T13:55:27.260Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-bydureon-pen-treatment-type-2-diabetes-03032014.html 2017-01-11T19:46:46.158Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-alderley-park-site-cheshire-uk-sale-11032014.html 2017-01-19T11:51:43.674Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-non-executive-director-ann-cairns-20032014.html 2017-01-19T13:09:37.429Z https://www.astrazeneca.com/media-centre/press-releases/2014/forxiga-approval-japan-type-2-diabetes-treatment-24032014.html 2017-01-19T13:35:40.883Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-sumitomo-chemicals-astrazeneca-kk-japan-26032014.html 2017-01-19T12:05:42.665Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-early-drug-discovery-centre-cambridge-uk-31032014.html 2017-01-19T11:39:04.590Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-first-quarter-results-2014-24042014.html 2017-07-06T13:56:48.509+01:00 https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-announcement-28042014.html 2017-01-19T13:52:37.493Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-proposal-announcement-02052014.html 2017-01-11T19:38:09.991Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-rejects-pfizer-proposal-02052014.html 2017-01-19T11:54:28.854Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-epanova-severe-hypertriglyceridaemia-treatment-06052014.html 2017-01-19T13:54:56.894Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-updated-strategy-value-for-shareholders-06052014.html 2017-01-19T12:08:59.358Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-immunotherapy-study-medi4736-lung-cancer-patients-08052014.html 2017-01-19T12:06:44.509Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-study-results-plaque-psoriasis-patients-09052014.html 2017-01-19T11:27:48.536Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-respiratory-data-ats-2014-international-conference-12052014.html 2017-01-19T12:07:35.589Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-medimmune-mavrilimumab-sifalimumab-studies-rheumatoid-arthritis-global-disease-12052014.html 2017-01-19T11:43:07.811Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-saxagliptin-dapagliflozin-combination-type-2-diabetes-patients-13052014.html 2017-01-19T11:51:11.464Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-updated-statement-regarding-pfizer-announcement-13052014.html 2017-01-11T19:38:33.633Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-incyte-immuno-oncology-combination-clinical-trial-14052014.html 2017-01-19T13:41:11.600Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-acceleration-asco-2014-14052014.html 2017-01-19T13:27:41.573Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-laboratory-molecular-biology-joint-research-fund-15052014.html 2017-01-19T11:39:29.904Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-late-stage-pipeline-acceleration-strategy-15052014.html 2017-01-19T13:30:17.355Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-rejects-pfizers-final-proposal-19052014.html 2017-01-19T12:05:26.895Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-clarification-regarding-pfizer-statement-20052014.html 2017-01-19T13:30:02.094Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-withdrawal-26052014.html 2017-01-11T19:38:41.791Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-olaparib-cediranib-combination-data-ovarian-cancer-treatment-31052014.html 2017-01-19T13:28:14.615Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-progress-asco-2014-03062014.html 2017-01-19T13:27:55.375Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-novel-antibiotic-azd0914-us-fda-fast-track-03062014.html 2017-01-19T13:28:29.392Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-diabetes-data-american-diabetes-association-scientific-sessions-11062014.html 2017-01-19T12:08:25.402Z https://www.astrazeneca.com/media-centre/press-releases/2014/brodalumab-treatment-psoriatic-arthritis-study-new-england-journal-medicine-11062014.html 2017-01-19T13:29:10.349Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-synairgen-sng001-novel-immuno-modulatory-therapy-asthma-12062014.html 2017-01-19T12:07:01.613Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-advisory-committee-movantik-cardiovascular-safety-12062014.html 2017-01-19T13:53:32.980Z https://www.astrazeneca.com/media-centre/press-releases/2014/fda-advisory-committee-olaparib-ovarian-cancer-treatment-25062014.html 2017-01-19T13:32:14.278Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-global-research-development-centre-corporate-headquarters-cambridge-uk-18072014.html 2017-01-19T13:10:09.488Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-and-advaxis-partner-on-immuno-oncology-combination-clinical-trial-22072014.html 2017-01-19T13:40:32.287Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-qiagen-lung-cancer-diagnostic-test-iressa-treatment-28072014.html 2017-01-19T11:40:10.253Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-roche-azd9291-companion-diagnostic-test-lung-cancer-28072014.html 2017-01-19T11:40:57.792Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-kyowa-hakko-kirin-immuno-oncology-clinical-study-30072014.html 2017-01-19T11:36:35.794Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-almirall-respiratory-disease-30072014.html 2017-01-19T13:59:16.009Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-second-quarter-half-year-results-2014-31072014.html 2017-07-06T13:56:48.539+01:00 https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-lesinurad-xanthine-oxidase-results-gout-patients-13082014.html 2017-01-19T11:52:00.207Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-tralokinumab-treatment-severe-asthma-14082014.html 2017-01-19T13:59:32.161Z https://www.astrazeneca.com/media-centre/press-releases/2014/united-states-department-justice-closes-investigation-plato-clinical-trial-brilinta-19082014.html 2017-01-19T13:53:08.322Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-caz-avi-results-complicated-intra-abdominal-infections-19082014.html 2017-01-19T11:51:28.236Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-illumina-gene-sequencing-panel-companion-diagnostic-tests-oncology-21082014.html 2017-01-19T11:50:53.105Z https://www.astrazeneca.com/media-centre/press-releases/2014/brilinta-brilique-stemi-patients-cardiology-01092014.html 2017-01-19T13:45:05.417Z https://www.astrazeneca.com/media-centre/press-releases/2014/benralizumab-study-lancet-respiratory-medicine-08092014.html 2017-01-19T13:28:43.059Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-diabetes-research-2014-meeting-european-association-study-of-diabetes-10092014.html 2017-01-19T12:07:52.365Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-lilly-bace-inhibitor-azd3293-alzheimers-disease-16092014.html 2017-01-19T11:37:12.105Z https://www.astrazeneca.com/media-centre/press-releases/2014/fda-approved-movatnik-opioid-induced-constipation-chronic-non-cancer-pain-patients-16092014.html 2017-01-19T13:34:11.957Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-exenatide-study-results-byetta-type-2-diabetes-patients-19092014.html 2017-01-19T13:52:53.260Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-cancer-research-uk-cruk-media-alliance-laboratory-biologic-cancer-medicines-25092014.html 2017-01-19T13:38:22.309Z https://www.astrazeneca.com/media-centre/press-releases/2014/iressa-chmp-positive-opinion-blood-based-diagnostic-testing-european-label-26092014.html 2017-01-11T18:47:49.048Z https://www.astrazeneca.com/media-centre/press-releases/2014/moventig-naloxegol-chmp-positive-opinion-opioid-induced-constipation-treatment-26092014.html 2017-01-11T18:48:03.305Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-progress-esmo-2014-congress-27092014.html 2017-01-19T12:07:17.761Z https://www.astrazeneca.com/media-centre/press-releases/2014/benralizumab-study-positive-results-severe-asthma-lancet-respiratory-medicine-09102014.html 2017-01-19T13:51:31.554Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-university-cambridge-partnership-16102014.html 2017-01-19T13:27:22.752Z https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-positive-chmp-opinion-ovarian-cancer-treatment-24102014.html 2017-01-19T13:36:50.610Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-xigduo-type-2-diabetes-patients-30102014.html 2017-01-19T13:55:12.029Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-healthy-heart-africa-programme-hypertension-28102014.html 2017-01-19T13:08:31.371Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-almirall-respiratory-disease-transaction-complete-03112014.html 2017-01-19T12:05:59.702Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-pharmacyclics-oncology-clinical-trial-collaborations-04112014.html 2017-01-19T11:39:48.739Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-pharmacyclics-janssen-immuno-oncology-combination-trials-haematological-cancers-04112014.html 2017-01-19T13:58:38.666Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-immuno-oncology-capabilities-definiens-04112014.html 2017-01-19T13:58:56.994Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-myalept-aegerion-leptin-deficiency-06112014.html 2017-01-19T12:08:40.465Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-third-quarter-nine-months-results-2014-06112014.html 2017-07-06T13:56:48.482+01:00 https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-inflammation-autoimmunity-pipeline-data-american-college-rheumatology-2014-annual-meeting-11112014.html 2017-01-19T12:08:08.648Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-study-positive-results-plaque-psoriasis-patients-11112014.html 2017-01-19T11:28:24.400Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-isis-pharmaceuticals-oligonucleotide-oncology-cardiovascular-metabolic-diseases-13112014.html 2017-01-19T11:31:49.709Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-brilinta-development-programme-cardiovascular-13112014.html 2017-01-19T11:42:27.681Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-strategy-update-institutional-investors-financial-analysts-18112014.html 2017-01-19T13:10:43.747Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-successful-pricing-euro-medium-term-notes-19112014.html 2017-01-19T13:08:16.661Z https://www.astrazeneca.com/media-centre/press-releases/2014/duaklir-genuiar-approved-european-union-chronic-obstructive-pulmonary-disease-24112014.html 2017-01-19T13:30:30.843Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-final-study-positive-results-plaque-psoriasis-25112014.html 2017-01-19T11:28:41.731Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-definiens-aquisition-tissue-phenomics-26112014.html 2017-01-19T13:42:16.793Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-eli-lilly-clinical-trial-early-alzheimers-disease-patients-01122014.html 2017-01-19T11:30:13.348Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-accept-new-drug-application-iressa-lung-cancer-02122014.html 2017-01-19T13:49:38.721Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-nexium-antitrust-litigation-jury-verdict-05122014.html 2017-01-19T13:35:55.715Z https://www.astrazeneca.com/media-centre/press-releases/2014/moventig-approved-european-union-opioid-induced-constipation-09122014.html 2017-01-19T13:43:46.260Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-amagine-1-results-brodalumab-plaque-psoriasis-11122014.html 2017-01-19T11:29:10.972Z https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-approved-european-union-brca-mutated-ovarian-cancer-treatment-18122014.html 2017-01-19T13:38:02.395Z https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-approved-us-fda-brca-mutated-ovarian-cancer-treatment-19122014.html 2017-01-19T13:37:07.439Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-max-planck-institute-satellite-chemistry-unit-cardiovascular-metabolic-diseases-08072014.html 2017-01-19T11:38:08.165Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mitsubishi-tanabe-pharma-corporation-diabetic-nephropathy-20082014.html 2017-01-19T11:38:42.563Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-scientists-cancer-research-uk-cambridge-institute-17022014.html 2017-01-19T13:10:29.310Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-shanghai-institutes-biological-sciences-cardiovascular-metabolic-diseases-research-23012014.html 2017-01-19T11:41:17.922Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-korea-health-industry-development-institute-oncology-research-programme-06032014.html 2017-01-19T11:32:08.730Z https://www.astrazeneca.com/media-centre/press-releases/2014/new-open-innovation-platform-compound-bank-partnering-programmes-25032014.html 2017-01-19T13:50:03.333Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-shenzhen-university-health-science-center-chronic-kidney-disease-27032014.html 2017-01-19T11:41:43.020Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-tianjin-medical-university-cardiovascular-research-china-15052014.html 2017-01-19T11:42:01.762Z https://www.astrazeneca.com/media-centre/press-releases/2014/nobel-laureate-tim-hunt-nobel-prize-inspiration-initiative-astrazeneca-china-03062014.html 2017-01-19T13:50:31.742Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-addc-novel-drug-development-academic-research-community-17062014.html 2017-01-18T15:31:50.233Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-technology-novel-targets-discovery-research-03072014.html 2017-01-19T13:44:12.725Z https://www.astrazeneca.com/media-centre/press-releases/2014/pharma-companies-astrazeneca-virtual-library-pharmaceutical-compounds-22072014.html 2017-01-19T13:52:19.040Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-redx-pharma-genetic-drivers-tumour-growth-research-03092014.html 2017-01-19T11:40:32.597Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-fda-medi3902-nosocomial-pneumonia-prevention-23092014.html 2017-01-19T13:43:06.590Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-cancer-research-uk-new-cancer-medicine-screening-mrc-uk-centre-lead-discovery-28112014.html 2017-01-19T13:57:34.794Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-shionogi-crestor-licence-agreement26122013.html 2017-01-19T09:57:24.079Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-global-diabetes-alliance-assets-19122013.html 2017-01-19T09:58:09.323Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-statement-esomeprazole-strontium-product-launch-17122013.html 2017-01-19T09:58:23.737Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-lesinurad-study-results-gout-patients-13122013.html 2017-01-19T09:59:15.199Z https://www.astrazeneca.com/media-centre/press-releases/2013/fda-advisory-committee-recommends-dapagliflozin-type-2-diabetes-treatment-12122013.html 2017-01-19T09:59:32.607Z https://www.astrazeneca.com/media-centre/press-releases/2013/fda-advisory-committee-metreleptin-lipodystrophy-treatment-12122013.html 2017-01-19T09:59:45.985Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-brixham-environmental-laboratory-plymouth-university-09122013.html 2017-01-19T10:00:00.800Z https://www.astrazeneca.com/media-centre/press-releases/2013/fluenz-tetra-european-commission-approval-seasonal-influenza-prevention-children-06122013.html 2017-01-19T10:00:21.002Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-prilosec-patent-litigation-ruling-03122013.html 2017-01-19T10:00:56.306Z https://www.astrazeneca.com/media-centre/press-releases/2013/xigduo-chmp-positive-opinion-european-union-type-2-diabetes-treatment-22112013.html 2017-01-19T10:01:12.142Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centre-corporate-headquarters-cambridge-uk-herzog-meuron-architect-19112013.html 2017-01-19T10:02:41.007Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-fda-new-drug-application-naloxegol-opioid-induced-constipation-treatment-19112013.html 2017-01-19T10:03:01.971Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-manufacturing-facility-macclesfield-zoladex-prostate-cancer-treatment-11112013.html 2017-01-19T10:04:18.201Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-third-quarter-nine-months-results-2013-31102013.html 2017-01-19T10:04:57.827Z https://www.astrazeneca.com/media-centre/press-releases/2013/marc-dunoyer-new-chief-financial-officer-astrazeneca-31102013.html 2017-01-19T10:05:36.841Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-pulmicort-respules-patent-litigation-decision-30102013.html 2017-01-19T10:05:53.656Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-benralizumab-severe-asthma-treatment-30102013.html 2017-01-19T10:06:31.539Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-brixham-environmental-laboratory-closing-24102013.html 2017-01-19T10:06:45.628Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-selumetinib-non-small-cell-lung-cancer-treatment-22102013.html 2017-01-19T10:07:10.273Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oncology-medimmune-spirogen-acquisition-15102013.html 2017-01-19T10:07:26.834Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-janssen-japan-prostate-cancer-treatment-11102013.html 2017-01-19T10:07:41.507Z https://www.astrazeneca.com/media-centre/press-releases/2013/medimmune-amplimmune-aquisition-07102013.html 2017-01-19T10:07:57.071Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-lifts-temporary-injunction-hanmi-505b2-nda-esomeprazole-strontium-02102013.html 2017-01-19T10:08:20.591Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-alderley-park-biohub-research-development-centre-01102013.html 2017-01-19T10:08:33.853Z https://www.astrazeneca.com/media-centre/press-releases/2013/olaparib-european-medicines-agency-brca-mutated-ovarian-cancer-treatment-27092013.html 2017-01-19T10:08:48.159Z https://www.astrazeneca.com/media-centre/press-releases/2013/naloxegol-european-medicines-agency-opioid-induced-constipation-treatment-27092013.html 2017-01-19T10:09:07.936Z https://www.astrazeneca.com/media-centre/press-releases/2013/onglyza-hypoglycemia-pancreatitis-subanalyses-savor-cardiovascular-trial-outcomes-easd-26092013.html 2017-01-19T10:09:32.667Z https://www.astrazeneca.com/media-centre/press-releases/2013/dapagliflozin-hba1c-type-2-diabetes-patients-metformin-sulfonylurea-24092013.html 2017-01-19T10:09:57.790Z https://www.astrazeneca.com/media-centre/press-releases/2013/fluenz-tetra-nasal-spray-vaccine-eu-chmp-positive-opinion-seasonal-influenza-prevention-children-20092013.html 2017-01-19T10:10:20.858Z https://www.astrazeneca.com/media-centre/press-releases/2013/fda-new-drug-application-epanova-severe-hypertriglyceridaemia-treatment-18092013.html 2017-01-19T10:10:35.145Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-temporary-injunction-hanmi-505b2-nda-esomeprazole-strontium-13092013.html 2017-01-19T10:11:29.707Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-merck-wee1-kinase-inhibitor-therapy-cancer-11092013.html 2017-01-19T10:12:35.584Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-olaparib-clinical-programme-brca-mutated-ovarian-cancer-treatment-04092013.html 2017-01-19T10:13:34.781Z https://www.astrazeneca.com/media-centre/press-releases/2013/onglyza-saxagliptin-safety-cardiovascular-heart-attack-stroke-02092013.html 2017-01-19T10:13:53.926Z https://www.astrazeneca.com/media-centre/press-releases/2013/medimmune-immune-mediated-cancer-therapy-amplimmune-26082013.html 2017-01-19T10:14:09.498Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-second-quarter-half-year-results-2013-01082013.html 2017-01-19T10:14:28.144Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-fibrogen-fg4592-anaemia-treatment-chronic-kidney-disease-renal-disease-31072013.html 2017-01-19T10:14:43.602Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-fda-new-drug-application-dapagliflozin-type-2-diabetes-treatment-25072013.html 2017-01-19T10:15:02.786Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-dapagliflozin-type-2-diabetes-treatment-25072013.html 2017-01-19T10:15:55.904Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-chief-financial-officer-simon-lowth-15072013.html 2017-01-19T10:16:17.992Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-university-cambridge-cancer-research-09072013.html 2017-01-19T10:16:53.674Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-pearl-therapeutics-acquisition-28062013.html 2017-01-19T10:18:07.349Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-savor-timi-53-results-onglyza-cardiovascular-trial-outcomes-19062013.html 2017-01-19T10:20:21.169Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-new-global-research-development-centre-corporate-headquarters-cambridge-uk-18062013.html 2017-01-19T10:21:08.999Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-ngm-biopharamaceuticals-diabetes-obesity-therapies-17062013.html 2017-01-19T10:21:33.964Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-pearl-therapeutics-respiratory-disease-10062013.html 2017-01-19T10:22:12.193Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oskira-trials-fostamatinib-results-04062013.html 2017-01-19T10:22:30.023Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-hanmi-pharmaceuticals-amneal-pharmaceuticals-us-nexium-patent-litigation-03062013.html 2017-01-19T10:22:50.653Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-omthera-pharmaceuticals-dyslipidemia-treatment-cardiovascular-28052013.html 2017-01-19T10:23:43.529Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-temporary-injunction-pulmicort-respules-25052013.html 2017-01-19T10:23:15.215Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-accelerated-oncology-pipeline-2013-asco-annual-meeting-16052013.html 2017-01-19T10:24:12.482Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-alderley-park-cheshire-future-29042013.html 2017-01-19T10:24:38.099Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-first-quarter-results-2013-25042013.html 2017-01-19T10:24:56.404Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bind-therapeutics-cancer-nanomedicine-accurin-22042013.html 2017-01-19T10:25:13.131Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oskira-1-study-results-fostamatinib-rheumatoid-arthritis-05042013.html 2017-01-19T10:25:35.137Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-alphacore-pharma-biologics-03042013.html 2017-01-19T10:25:58.563Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-district-court-pulmicort-respules-patent-invalid-02042013.html 2017-01-19T10:26:21.903Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-crestor-patent-litigation-settled-25032013.html 2017-01-19T10:26:39.622Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-marc-dunoyer-executive-vice-president-global-portfolio-product-strategy-21032013.html 2017-01-19T10:26:55.694Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-growth-scientific-leadership-strategy-21032013.html 2017-01-19T10:27:56.421Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-karolinska-institutet-research-centre-cardiovascular-metabolic-disease-regnerative-medicine-21032013.html 2017-01-19T10:29:22.187Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-moderna-therapeutics-cardiometabolic-diseases-cancer-treatment-21032013.html 2017-01-19T10:29:51.588Z https://www.astrazeneca.com/media-centre/press-releases/2013/copd-medicines-pathos-study-journal-internal-medicine-19032013.html 2017-01-19T10:31:07.448Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centres-innovation-pipeline-18032013.html 2017-01-19T10:31:33.981Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centre-global-headquarters-cambridge-18032013.html 2017-01-19T10:32:58.874Z https://www.astrazeneca.com/media-centre/press-releases/2013/australia-federal-court-crestor-patents-05032013.html 2017-01-19T10:33:17.810Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-naloxegol-long-term-safety-opioid-induced-constipation-patients-26022013.html 2017-01-19T10:33:44.953Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-court-appeals-seroquel-patent-descision-15022013.html 2017-01-19T10:34:01.469Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-fourth-quarter-full-year-results-2012-31012013.html 2017-07-06T13:56:48.498+01:00 https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-senior-executive-team-15012013.html 2017-07-06T11:58:42.207+01:00 https://www.astrazeneca.com/media-centre/press-releases/2012.html 2016-11-22T17:02:18.764Z https://www.astrazeneca.com/media-centre/press-releases/2012/astrazeneca-reaffirms-december-2011-financial-guidance-for-2011-.html 2017-01-13T08:32:51.014Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-IMS-Health-announce-real-world-evidence-collaboration-in-Europe-11012015.html 2017-01-13T08:27:57.485Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Bristol-Myers-Squibb-receive-complete-response-letter-from-US-Food-and-Drug-Administration-for-dapagliflozin-19012012.html 2017-01-13T08:27:44.564Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Fourth-quarter-and-full-year-results-2011-02022012.html 2017-07-06T13:56:48.536+01:00 https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZenecas-new-restructuring-initiatives-to-drive-productivity-and-support-innovation-02022012.html 2017-01-13T08:33:27.895Z https://www.astrazeneca.com/media-centre/press-releases/2012/European-Commission-approves-CAPRELSA-vandetanib-for-patients-with-advanced-medullary-thyroid-cancer-21022012.html 2017-01-13T08:39:34.639Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-Non-Executive-changes-retirement-of-Chairman-and-appointment-of-successor-01032012.html 2017-01-13T08:29:42.144Z https://www.astrazeneca.com/media-centre/press-releases/2012/FDA-approves-first-four-strain-flu-vaccine-01032012.html 2017-01-13T08:54:19.469Z https://www.astrazeneca.com/media-centre/press-releases/2012/FDA-responds-AstraZeneca-Citizen-Petitions-quetiapine-product-labelling-09032012.html 2017-01-13T08:56:12.933Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-files-against-the-fda-for-decision-on-quetiapine-13032012.html 2017-01-13T08:31:04.091Z https://www.astrazeneca.com/media-centre/press-releases/2012/Remaining-TC-5214-Phase-III-efficacy-studies-do-not-meet-endpoint-regulatory-filing-will-not-be-pursued-20032012.html 2017-01-13T08:59:12.568Z https://www.astrazeneca.com/media-centre/press-releases/2012/UK-court-finds-SEROQUEL-XR-formulation-patent-invalid-22032012.html 2017-01-13T08:59:34.212Z https://www.astrazeneca.com/media-centre/press-releases/2012/US-court-denies-preliminary-injunction-application-against-the-FDA-and-dismisses-AstraZenecas-lawsuit-without-prejudice-26032012.html 2017-01-13T09:00:04.920Z https://www.astrazeneca.com/media-centre/press-releases/2012/US-District-Court-finds-SEROQUEL-XR-formulation-patent-valid-and-infringed-30032012.html 2017-01-13T09:00:23.425Z https://www.astrazeneca.com/media-centre/press-releases/2012/astrazeneca-and-amgen-announce-collaboration-02042012.html 2017-01-13T08:26:59.671Z https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-type-2-diabetes-20042012.html 2017-01-13T08:56:59.604Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-to-acquire-Ardea-Biosciences-for-1-billion-23042012.html 2017-01-13T08:34:19.556Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-The-Medicines-Company-announce-global-collaboration-in-acute-ischaemic-heart-disease-25042012.html 2017-01-13T08:29:11.414Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-First-quarter-results-2012-26042012.html 2017-07-06T13:56:48.546+01:00 https://www.astrazeneca.com/media-centre/press-releases/2012/David-Brennan-to-retire-as-AstraZenecas-Chief-Executive-Officer-26042012.html 2017-01-13T08:38:45.397Z https://www.astrazeneca.com/media-centre/press-releases/2012/Innovative-public-private-collaboration-launches-to-tackle-antibiotic-research-24052012.html 2017-01-13T08:57:16.438Z https://www.astrazeneca.com/media-centre/press-releases/2012/Investigational-compound-dapagliflozin-demonstrated-significant-reductions-in-blood-sugarlevels-09062012.html 2017-01-13T08:58:24.948Z https://www.astrazeneca.com/media-centre/press-releases/2012/Zinforo-ceftaroline-fosamil-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-patients-with-serious-skin-infections-or-community-acquired-pneumonia-22062012.html 2017-01-13T09:00:39.497Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Merck-agree-to-amend-second-option-27062012.html 2017-01-13T08:28:39.554Z https://www.astrazeneca.com/media-centre/press-releases/2012/Bristol-Myers-Squibb-and-AstraZeneca-expand-diabetes-alliance-30062012.html 2017-01-13T08:34:34.545Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-completes-sale-of-Aptium-Oncology-assets-06072012.html 2017-01-13T08:30:28.871Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-reports-terms-of-David-Brennans-retirement-16072012.html 2017-01-13T08:33:07.005Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Second-quarter-and-half-year-results-2012-26072012.html 2017-07-06T13:56:48.520+01:00 https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Bristol-Myers-Squibb-complete-expansion-of-diabetes-alliance-through-Bristol-Myers-Squibbs-acquisition-of-Amylin-Pharmaceuticals-09082012.html 2017-01-13T08:27:31.129Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Pfizer-enter-agreement-for-over-the-counter-NEXIUM-AstraZeneca-raises-2012-guidance-13082012.html 2017-01-13T08:28:54.072Z https://www.astrazeneca.com/media-centre/press-releases/2012/Pascal-Soriot-appointed-Chief-Executive-Officer-of-AstraZeneca-28082012.html 2017-01-13T08:58:48.872Z https://www.astrazeneca.com/media-centre/press-releases/2012/European-Commission-approves-ZINFORO-ceftaroline-fosamil-for-adult-patients-with-serious-skin-infections-or-community-acquired-pneumonia-28082012.html 2017-01-13T08:43:06.453Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-prices-a-2-billion-bond-issue-12092012.html 2017-01-13T08:32:20.773Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-suspends-share-repurchase-programme-01102012.html 2017-01-13T08:33:59.194Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Ardelyx-announce-worldwide-licensing-deal-for-NHE3-inhibitor-programme-for-complications-of-renal-disease-including-diabetes-induced-renal-disease-08102012.html 2017-01-13T08:27:12.996Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Ironwood-announce-Linaclotide-collaboration-23102012.html 2017-01-13T08:28:10.726Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Third-quarter-and-nine-months-results-2012-25102012.html 2017-07-06T13:56:48.495+01:00 https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-details-of-Chief-Executive-Officer-Pascal-Soriot-remuneration-29102012.html 2017-01-13T08:29:26.925Z https://www.astrazeneca.com/media-centre/press-releases/2012/Alzheimers-cancer-and-rare-disease-research-to-benefit-from-landmark-MRC-AstraZeneca-compound-collaboration-31102012.html 2017-01-13T08:26:47.935Z https://www.astrazeneca.com/media-centre/press-releases/2012/Definition-of-Core-Financial-Measures-12112012.html 2017-01-13T08:39:03.020Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-top-line-phase-III-results-from-naloxegol-pivotal-trials-in-patients-with-opioid-induced-constipation-12112012.html 2017-01-13T08:29:56.166Z https://www.astrazeneca.com/media-centre/press-releases/2012/Court-in-Germany-finds-SEROQUEL-XR-formulation-patent-invalid-13112012.html 2017-01-13T08:35:54.975Z https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-now-approved-in-European-Union-for-treatment-of-type-2-diabetes-14112012.html 2017-01-13T08:56:41.008Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Isis-Pharmaceuticals-form-strategic-alliance-on-RNA-therapeutics-for-cancer-11122012.html 2017-01-13T08:28:25.279Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-top-line-results-of-OSKIRA-4-Phase-IIb-study-of-fostamatinib-as-a-monotherapy-for-rheumatoid-arthritis-13122012.html 2017-01-13T08:30:12.849Z https://www.astrazeneca.com/media-centre/press-releases/2012/CRESTOR-US-patent-upheld-by-Court-of-Appeals-for-the-Federal-Circuit-14122012.html 2017-01-13T08:36:10.261Z https://www.astrazeneca.com/media-centre/press-releases/2011.html 2016-11-22T17:02:28.272Z https://www.astrazeneca.com/media-centre/press-releases/2011/us-food-and-drug-administration-extend-review-timeline-for-vand-07012011.html 2017-01-19T13:43:19.199Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-replies-to-the-us-fda-complete-response-letter-for-b-21012011.html 2017-01-19T13:43:36.405Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-plc-fourth-quarter-and-full-year-results-2010-27012011.html 2017-01-19T13:43:48.556Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-approves-nasal-spray-vaccine-Fluenz-for-flu-01022011.html 2017-01-19T13:43:59.966Z https://www.astrazeneca.com/media-centre/press-releases/2011/US-FDA-Assigns-new-PDUFA-date-for-BRILINTA-ticagrelor-tablets-04022011.html 2017-01-19T13:44:18.030Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-halts-phase-iii-trial-of-zibotentan-in-non-metastatic-castrate-resistant-07022011.html 2017-01-19T13:44:37.026Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-and-targacept-initiate-phase-iib-clinical-trial-of-tc-5214-07022011.html 2017-01-19T13:44:53.007Z https://www.astrazeneca.com/media-centre/press-releases/2011/onglyza_-us-label-update-provides-further-evidence-regarding-use-23022011.html 2017-01-19T13:45:07.790Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-to-discontinue-production-of-pulmicort--pmdi--other-07032011.html 2017-01-19T13:45:20.758Z https://www.astrazeneca.com/media-centre/press-releases/2011/Onglyza-is-first-DPP4-Inhibitor-for-Type-2-Diabetes-04032011.html 2017-01-19T13:45:35.264Z https://www.astrazeneca.com/media-centre/press-releases/2011/-fda-accepts-new-drug-application-for-investigational-compound-08032011.html 2017-01-19T13:45:49.337Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-initiates-phase-iii-clinical-programme-evaluating-nk-15032011.html 2017-01-19T13:46:03.053Z https://www.astrazeneca.com/media-centre/press-releases/2011/uk-and-us-governments-reach-agreement-over-astrazeneca-tax-matte-28032011.html 2017-01-19T13:46:17.832Z https://www.astrazeneca.com/media-centre/press-releases/2011/fda-approves-orphan-drug-vandetanib-07042011.html 2017-01-19T13:48:59.815Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-PLC-First-Quarter-Results-2011-28042011.html 2017-07-06T13:56:48.499+01:00 https://www.astrazeneca.com/media-centre/press-releases/2011/health-economics-substudy-of-plato-shows-brilique-to-be-cost-effective-09052011.html 2017-01-19T13:49:27.463Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-signs-agreement-in-japan-with-daiichi-sankyo-to-co-promote-24052011.html 2017-01-19T13:49:40.355Z https://www.astrazeneca.com/media-centre/press-releases/2011/health-canada-approves-brilinta--ticagrelor-tablets-01062011.html 2017-01-19T13:49:54.874Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-extends-its-investment-in-russia-with-new-predictive-science-centre-16062011.html 2017-01-19T13:50:08.174Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-sell-AstraTech-to-DENTSPLY-International-22062011.html 2017-01-19T13:50:21.849Z https://www.astrazeneca.com/media-centre/press-releases/2011/Bristol-Myers-Squibb-and-AstraZeneca-ph3-study-on-DAPAGLIFLOZIN-27062011.html 2017-01-19T13:50:37.816Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-s-nexium-receives-first-regulatory-approval-in-japan-01072011.html 2017-01-19T13:51:08.153Z https://www.astrazeneca.com/media-centre/press-releases/2011/fda-advisory-committee-makes-recommendation-on-investigational-compound-20072011.html 2017-01-19T13:51:20.664Z https://www.astrazeneca.com/media-centre/press-releases/2011/fda-approves-new-medicine-brilinta--ticagrelor--for-use-in-the-us-20072011.html 2017-01-19T13:51:34.492Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-plc-second-quarter-and-half-year-results-2011-28072011.html 2017-01-19T13:51:47.625Z https://www.astrazeneca.com/media-centre/press-releases/2011/positive-agreement-received-for-approval-of-axanum-in-europe-02082011.html 2017-01-19T13:52:01.383Z https://www.astrazeneca.com/media-centre/press-releases/2011/sale-of-astra-tech-to-dentsply-international-complete-31082011.html 2017-01-19T13:52:14.033Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-announces-top-line-results-from-saturn-study-020920111.html 2017-01-19T13:52:26.794Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-announces-top-line-results-from-saturn-study-02092011.html 2017-01-19T13:52:52.336Z https://www.astrazeneca.com/media-centre/press-releases/2011/KOMBOGLYZE-saxagliptin-and-metformin-HCl-immediate-release-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-type-2-diabetes-23092011.html 2017-01-19T13:53:06.560Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-announces-first-approval-of-FASLODEX-fulvestrant-in-Japan-26092011.html 2017-01-19T13:59:10.874Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-enters-into-a-settlement-agreement-with-Handa-Pharmaceuticals-regarding-US-SEROQUEL-XR-patent-litigation-29092011.html 2017-01-19T13:58:56.224Z https://www.astrazeneca.com/media-centre/press-releases/2011/BRILIQUE-receives-a-positive-preliminary-medical-benefit-assessment-for-the-majority-of-ACS-patients-in-Germany-as-part-of-new-AMNOG-review-process-04102011.html 2017-01-19T13:58:40.729Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-enters-into-a-settlement-agreement-with-Accord-Healthcare-Inc-and-Intas-Pharmaceuticals-Ltd-regarding-US-SEROQUEL-XR-patent-litigation-05102011.html 2017-01-19T13:58:25.720Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-increases-investment-in-China-with-new-200-million-manufacturing-facility-10102011.html 2017-01-19T13:57:15.656Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-and-Forest-Laboratories-to-initiate-phase-III-clinical-trials-for-ceftazidime-avibactam-to-treat-serious-Gram-negative-bacterial-infections-18102011.html 2017-01-19T13:57:01.312Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-present-new-healthcare-economics-data-demonstrating-cost-effectiveness-of-BRILIQUE-at-ISPOR-EU-21102011.html 2017-07-06T13:56:48.526+01:00 https://www.astrazeneca.com/media-centre/press-releases/2011/US-Food-and-Drug-Administration-extends-action-date-for-dapagliflozin-by-three-months-26102011.html 2017-01-19T13:56:34.470Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-PLC-Third-quarter-and-nine-months-results-2011-27102011.html 2017-07-06T13:56:48.487+01:00 https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-and-Targacept-announce-first-top-line-Phase-III-results-for-TC-5214-as-an-adjunct-treatment-in-patients-with-major-depressive-disorder-08112011.html 2017-01-19T13:56:07.306Z https://www.astrazeneca.com/media-centre/press-releases/2011/SATURN-demonstrated-effect-of-intensive-statin-treatment-on-reducing-atherosclerosis-15112011.html 2017-01-19T13:55:54.432Z https://www.astrazeneca.com/media-centre/press-releases/2011/CAPRELSA-vandetanib-receives-positive-CHMP-opinion-in-the-European-Union-for-treating-advanced-medullary-thyroid-cancer-18112011.html 2017-01-19T13:55:39.622Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-commits-100-million-MedImmune-Ventures-28112011.html 2017-01-19T13:55:27.075Z https://www.astrazeneca.com/media-centre/press-releases/2011/KOMBOGLYZE-receives-marketing-authorisation-in-the-European-Union-for-adult-patients-with-Type-2-diabetes-29112011.html 2017-01-19T13:55:13.566Z https://www.astrazeneca.com/media-centre/press-releases/2011/Groundbreaking-scientific-collaboration-gives-UK-academia-access-to-compounds-to-advance-medical-research-05122011.html 2017-01-19T13:55:00.834Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-streamline-US-sales-organisation-07122011.html 2017-01-19T13:54:47.537Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-acquire-generics-company-to-broaden-patient-access-to-medicines-in-China-08122011.html 2017-01-19T13:54:32.784Z https://www.astrazeneca.com/media-centre/press-releases/2011/G-BA-issues-positive-final-medical-benefit-assessment-for-BRILIQUE-in-Germany-15122011.html 2017-01-19T13:54:20.312Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-updates-on-olaparib-and-TC-5214-development-programmes-20122010.html 2017-01-19T13:54:07.467Z https://www.astrazeneca.com/media-centre/press-releases/2010.html 2016-11-22T17:02:41.616Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-Agreements-With-Teva-Pharmaceuticals-Regarding-Nexium-And-Prilosec-US-Patent-Litigations-07012010.html 2017-01-19T12:52:13.821Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-Fourth-Quarter-and-Full-Year-Results-2009-28012010.html 2017-07-06T13:56:48.529+01:00 https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Approves-New-Indication-for-Crestor-Rosuvastatin-Calcium-09022010.html 2017-01-19T12:52:43.366Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Rigel-Pharmaceuticals-Sign-Worldwide-License-Agreement-for-Late-Stage-Development-Product-Fostamatinib-Disodium-R788-for-the-Treatment-of-Rheumatoid-Arthritis-16022010.html 2017-01-19T12:53:08.092Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-Agreement-With-UK-Tax-Authorities-Over-Transfer-Pricing-23022010.html 2017-01-19T12:54:44.161Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Provides-An-Update-On-The-Status-Of-Its-Arrangements-With-Merck-01032010.html 2017-01-19T12:54:57.308Z https://www.astrazeneca.com/media-centre/press-releases/2010/RECENTIN-did-not-meet-primary-endpoint-in-Horizon-III-study-in-metastatic-colorectal-cancer-08032010.html 2017-01-19T12:55:10.372Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Comments-On-FDA-Joint-Advisory-Committee-Meeting-On-Post-Marketing-Safety-Studies-For-The-Use-Of-LABAs-In-Asthma-11032010.html 2017-01-19T12:55:30.783Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Extends-Branded-Generics-Capability-With-Torrent-Agreement-11032010.html 2017-01-19T12:55:45.502Z https://www.astrazeneca.com/media-centre/press-releases/2010/New-PLATO-Sub-Analysis-of-CABG-Patients-Presented-at-ACC-16032010.html 2017-01-19T12:56:01.401Z https://www.astrazeneca.com/media-centre/press-releases/2010/Jury-Rules-In-Favour-Of-AstraZeneca-In-First-US-Seroquel-Product-Liability-Trial-18032010.html 2017-01-19T12:56:17.032Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Abbott-receive-FDA-complete-response-letter-on-CERTRIAD-new-drug-application-30032010.html 2017-01-19T12:56:29.736Z https://www.astrazeneca.com/media-centre/press-releases/2010/Seroquel-XR-Recommended-For-Approval-In-EU-as-an-Add-On-Treatment-Of-Major-Depressive-Disorder-23042010.html 2017-01-19T12:56:49.347Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Finalises-US-Agreement-On-SEROQUEL-Marketing-27042010.html 2017-01-19T12:57:05.003Z https://www.astrazeneca.com/media-centre/press-releases/2010/Crestor-Gains-New-EU-Indication-to-Prevent-Major-Cardiovascular-Events-in-High-Risk-Patients-27042010.html 2017-01-19T12:57:21.544Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-First-Quarter-Results-2010-29042010.html 2017-07-06T13:56:48.525+01:00 https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-approved-VIMOVO-for-arthritis-patients-at-risk-of-developing-NSAID-associated-gastric-ulcers-30042010.html 2017-01-19T12:57:53.133Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-US-Agreement-With-Teva-Pharmaceuticals-Regarding-Entocort-EC-Capsules-18052010.html 2017-01-19T12:58:08.143Z https://www.astrazeneca.com/media-centre/press-releases/2010/Martin-Mackay-to-Lead-AstraZenecas-Research-and-Development-Organisation-26052010.html 2017-01-19T12:58:23.561Z https://www.astrazeneca.com/media-centre/press-releases/2010/NOTICE-Advisory-Committee-Briefing-Materials-for-Motavizumab-BLA-Available-on-US-FDA-Web-Site-28052010.html 2017-01-19T12:58:36.872Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Announces-Results-of-Recentin-HORIZON-II-Phase-III-Trial-in-Metastatic-Colorectal-Cancer-28052010.html 2017-01-19T12:58:52.256Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Receives-FDA-Complete-Response-Letter-for-AXANUM-New-Drug-Application-01062010.html 2017-01-19T12:59:07.817Z https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-updates-US-product-labels-for-LABA-containing-medications-including-AstraZenecas-SYMBICORT-02062010.html 2017-01-19T12:59:23.855Z https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Advisory-Committee-Reviews-MedImmunes-Motavizumab-02062010.html 2017-01-19T12:59:41.734Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Submits-Marketing-Authorisation-Application-To-European-Union-For-Cardiovascular-Drug-Axanum-04062010.html 2017-01-19T12:59:58.957Z https://www.astrazeneca.com/media-centre/press-releases/2010/Federal-Court-of-Canada-Rules-on-Applications-for-Generic-Esomep-17062010.html 2017-01-19T13:00:12.978Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Targacept-Initiate-Phase-3-Clinical-Development-23062010.html 2017-01-19T13:00:27.065Z https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Resets-its-Decision-Date-For-Motavizumab-25062010.html 2017-01-19T13:00:40.096Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-MMV-Join-Efforts-in-the-Fight-Against-Malaria-28072010.html 2017-01-19T13:00:55.887Z https://www.astrazeneca.com/media-centre/press-releases/2010/CRESTOR-Patent-Upheld-By-US-Court-30072010.html 2017-01-19T13:28:55.736Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-MRC-Technology-Form-Strategic-Alliance-05072010.html 2017-01-19T13:29:25.541Z https://www.astrazeneca.com/media-centre/press-releases/2010/Advisory-Committee-Briefing-Materials-For-Brilinta-Ticagrelor-26072010.html 2017-01-19T13:29:58.044Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-Appoints-New-NonExecutive-Director-29072010.html 2017-01-19T13:28:23.676Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Second-Quarter-and-Half-Year-Results-2010-29072010.html 2017-07-06T13:56:48.479+01:00 https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Advisory-Committee-recommends-US-FDA-approval-of-Brilinta-29072010.html 2017-01-19T13:27:45.611Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Announces-Agreements-in-Principle-in-Seroquel-09082010.html 2017-01-19T13:25:27.517Z https://www.astrazeneca.com/media-centre/press-releases/2010/Genetic-substudy-shows-fewer-major-cardiovascular-events-with-ticagrelor-brilinta-29082010.html 2017-01-19T13:24:40.573Z https://www.astrazeneca.com/media-centre/press-releases/2010/MedImmune-receives-complete-response-letter-on-motavizumab-30082010.html 2017-01-19T13:24:19.792Z https://www.astrazeneca.com/media-centre/press-releases/2010/European-Commission-Issues-Positive-Decision-for-Approval-of-Seroquel-XR-as-an-Add-On-Treatment-of-Major-Depressive-Disorder-02092010.html 2017-01-19T13:23:59.354Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Extends-Review-Timeline-For-BRILINTA-15092010.html 2017-01-19T13:23:40.974Z https://www.astrazeneca.com/media-centre/press-releases/2010/24-Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-Improved-Glycosylated-Hemoglobin-HbA1c-When-Added-to-Glimepiride-in-Adults-with-Type-2-Diabetes-Mellitus-20092010.html 2017-01-19T13:23:12.736Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-and-EU-regulatory-submissions-for-VANDETANIB-in-advanced-medullary-thyroid-cancer-23092010.html 2017-01-19T13:22:44.348Z https://www.astrazeneca.com/media-centre/press-releases/2010/52Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-24092010.html 2017-01-19T13:21:27.696Z https://www.astrazeneca.com/media-centre/press-releases/2010/BRILIQUE-ticagrelor-receives-positive-opinion-from-European-CHMP-for-the-treatment-of-Acute-Coronary-Syndromes-24092010.html 2017-01-19T13:21:14.142Z https://www.astrazeneca.com/media-centre/press-releases/2010/Results-of-Zibotentan-Phase-III-trial-in-castration-resistant-prostate-cancer-27092010.html 2017-01-19T13:21:01.106Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-initiates-phase-III-clinical-development-of-fostamatinib-29092010.html 2017-01-19T13:18:48.115Z https://www.astrazeneca.com/media-centre/press-releases/2010/New-outcomes-study-for-ticagrelor-BRILINTA-01102010.html 2017-01-19T13:18:32.911Z https://www.astrazeneca.com/media-centre/press-releases/2010/Positive-agreement-received-for-approval-of-VIMOVO-in-Europe-11102010.html 2017-01-19T13:18:18.847Z https://www.astrazeneca.com/media-centre/press-releases/2010/European-regulator-backs-nasal-spray-vaccine-FLUENZ-22102010.html 2017-01-19T13:10:58.735Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-initiates-phase-IIB-study-for-AZD9773-CytoFab-25102010.html 2017-01-19T13:10:44.197Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Third-Quarter-and-Nine-Months-Results-2010-28102010.html 2017-07-06T13:56:48.516+01:00 https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-announces-copromotion-agreement-with-Daiichi-Sankyo-29102010.html 2017-01-19T13:10:11.073Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-Appeal-Court-affirms-preliminary-injunction-against-Apotex-02112010.html 2017-01-19T13:09:59.017Z https://www.astrazeneca.com/media-centre/press-releases/2010/KOMBIGLYZE-XR-tablets-approved-in-the-US-05112010.html 2017-01-19T13:09:47.180Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-commences-review-of-strategic-options-for-Astra-Tech-19112010.html 2017-01-19T13:09:04.154Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Advisory-Committee-Makes-Recommendation-on-New-Drug-Application-for-Vandetanib-in-Advanced-Medullary-Thyroid-Cancer-02122010.html 2017-01-19T13:08:50.269Z https://www.astrazeneca.com/media-centre/press-releases/2010/Public-believe-China-and-India-set-to-become-World-leaders-for-innovation-survey-shows-06122010.html 2017-01-19T13:08:36.739Z https://www.astrazeneca.com/media-centre/press-releases/2010/European-Commission-Approves-Brilique-06122010.html 2017-01-19T13:07:01.797Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-appoints-new-Non-Executive-Director-17122010.html 2017-01-19T13:06:40.787Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-receives-complete-response-letter-from-US-FDA-for-BRILINTA-ticagrelor-tablets-17122010.html 2017-01-19T13:06:27.908Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-discontinues-motavizumab-RSV-21122010.html 2017-01-19T13:06:15.632Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-ends-agreement-with-Abbott-for-Certriad-22122010.html 2017-01-19T13:06:00.758Z https://www.astrazeneca.com/media-centre/press-releases/2009.html 2016-11-22T17:02:50.568Z https://www.astrazeneca.com/media-centre/press-releases/2009/MedImmune-Submits-Marketing-Authorisation-Application-06012009.html 2017-01-19T09:59:08.785Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Fourth-Quarter-and-Full-Year-Results-2008-29012009.html 2017-07-06T13:56:48.509+01:00 https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZenecas-Partner-POZEN-Informed-By-FDA-That-Gastric-Ulcers-Are-Valid-29062009.html 2017-01-19T10:00:03.058Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZenecas-partner-MAP-pharmaceuticals-Announces-24022009.html 2017-01-19T10:00:15.135Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-To-Participate-In-Tentative-FDA-Psychopharmacologic-Drugs-25022009.html 2017-01-19T10:01:00.451Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Board-Change-27022009.html 2017-01-19T10:01:13.399Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Receives-FDA-Complete-Response-Letter-On-Seroquel-27022009.html 2017-01-19T10:01:36.766Z https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Approves-Symbicort-for-Chronic-Obstructive-Pulmon-02032009.html 2017-01-19T10:01:48.957Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Issues-2008-Annual-Report-04032009.html 2017-01-19T10:02:01.629Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-to-Participate-in-Tentative-FDA-Psychopharmacologic-Drugs-Advisory-Committee-30032009.html 2017-01-19T10:02:16.036Z https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-Saxagliptin-Cardiovascular-Profile-Acceptable-02042009.html 2017-01-19T10:02:45.015Z https://www.astrazeneca.com/media-centre/press-releases/2009/David-Brennan-elected-board-chairman-of-the-Pharmaceutical-03042009.html 2017-01-19T10:02:59.290Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Receives-FDA-Complete-Response-Letter-on-Symbicort-06042009.html 2017-01-19T10:03:15.491Z https://www.astrazeneca.com/media-centre/press-releases/2009/Sale-of-AstraZeneca-OTC-Product-Portfolio-Cleared-06042009.html 2017-01-19T10:03:32.899Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Files-Suit-Against-Apotex-for-a-Declaratory-Judgment-07042009.html 2017-01-19T10:03:45.394Z https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Advisory-Committee-Recommendation-on-Seroquel-XR-09042009.html 2017-01-19T10:03:58.044Z https://www.astrazeneca.com/media-centre/press-releases/2009/Court-Grants-AstraZeneca-Temporary-Restraining-Order-17042009.html 2017-01-19T10:04:15.648Z https://www.astrazeneca.com/media-centre/press-releases/2009/IRESSA-Gefitinib-Recommended-for-Approval-23042009.html 2017-01-19T10:04:31.184Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-Food-and-Drug-Administration-Extends-Review-Timeline-23042009.html 2017-01-19T10:04:44.032Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-First-Quarter-Results-2009-23042009.html 2017-07-06T13:56:48.550+01:00 https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Announces-Top-Line-Results-From-Pivotal-11052009.html 2017-01-19T10:06:12.492Z https://www.astrazeneca.com/media-centre/press-releases/2009/Court-Grants-AstraZeneca-Preliminary-Injunction-Again-20052009.html 2017-01-19T10:06:46.170Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Regulatory-Update-on-Seroquel-XR-29052009.html 2017-01-19T10:07:12.750Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Merck-and-Co-Inc-Form-Pioneering-Collaboration-01062009.html 2017-01-19T10:07:26.423Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Abbott-Submit-New-Drug-Application-04062009.html 2017-01-19T10:07:39.917Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Abbott-Extend-Relationship-to-Include-04062009.html 2017-01-19T10:07:52.903Z https://www.astrazeneca.com/media-centre/press-releases/2009/Favourable-Vote-from-FDA-Advisory-Committee-on-Seroquel-10062009.html 2017-01-19T10:08:14.039Z https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-saxagliptin-Receives-Positive-Opinion-in-Europe-25062009.html 2017-01-19T10:08:30.795Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Development-Partner-Pozen-Inc-Submits-New-Drugs-30062009.html 2017-01-19T10:08:57.640Z https://www.astrazeneca.com/media-centre/press-releases/2009/IRESSA-Gefitinib-Receives-Marketing-Authorisation-01072009.html 2017-01-19T10:09:13.587Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-to-Advance-AZD3480-in-ADHD-08072009.html 2017-01-19T10:11:45.641Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Terminates-License-Agreement-with-MAP-09072009.html 2017-01-19T10:15:54.500Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Second-Quarter-and-Half-Year-Results-2009-30072009.html 2017-07-06T13:56:48.489+01:00 https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Approves-ONGLYZA-For-The-Treatment-Of-Type-2-Diabetes-01082009.html 2017-01-19T10:22:10.255Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-And-Astellas-Enter-Agreement-for-CoPromo-04082009.html 2017-01-19T10:22:40.874Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Forest-Laboratories-to-CoDevelop-and-Commercialise-12082009.html 2017-01-19T10:23:06.594Z https://www.astrazeneca.com/media-centre/press-releases/2009/Phase-III-Head-to-Head-Trial-Showed-Ticagrelor-Reduce-30082009.html 2017-01-19T10:24:27.945Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Announces-FDA-Acceptance-of-New-Drug-Application-31082009.html 2017-01-19T10:24:59.490Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Nektar-Sign-Worldwide-Agreement-for-Nektar-21092009.html 2017-01-19T10:25:28.092Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-Court-of-Appeals-Affirms-Summary-Judgment-Decision-25092009.html 2017-01-19T10:25:55.686Z https://www.astrazeneca.com/media-centre/press-releases/2009/Brilinta-Reduced-Cardiovascular-Deaths-and-Heart-Attacks-25092009.html 2017-01-19T10:26:25.712Z https://www.astrazeneca.com/media-centre/press-releases/2009/Seroquel-XR-and-Seroquel-Approved-in-Europe-for-Prevention-29092009.html 2017-01-19T10:26:57.566Z https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-saxagliptin-Receives-Marketing-Authorisation-05102009.html 2017-01-19T10:28:23.479Z https://www.astrazeneca.com/media-centre/press-releases/2009/Study-Finds-That-ONGLYZA-saxagliptin-When-Added-to-Metformin-05102009.html 2017-01-19T10:28:51.937Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-Food-and-Drug-Administration-Approves-CRESTOR-16102009.html 2017-01-19T10:31:11.524Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Submits-Marketing-Authorisation-Application-16102009.html 2017-01-19T10:40:10.549Z https://www.astrazeneca.com/media-centre/press-releases/2009/Patients-Taking-VIMOVOTM-Showed-Decrease-in-incidence-19102009.html 2017-01-19T10:42:14.780Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-withdraws-regulatory-submissions-for-Zactima-28102009.html 2017-01-19T10:43:13.372Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Third-Quarter-2009-29102009.html 2017-07-06T13:56:48.517+01:00 https://www.astrazeneca.com/media-centre/press-releases/2009/Discovery-Research-Leader-Leaves-AstraZeneca-13112009.html 2017-01-19T10:57:38.266Z https://www.astrazeneca.com/media-centre/press-releases/2009/BRILINTA-Demonstrated-Greater-Efficacy-Over-Clopidogrel-16112009.html 2017-01-19T10:57:58.346Z https://www.astrazeneca.com/media-centre/press-releases/2009/Results-from-Two-Phase-II-Trials-Add-to-Understanding-18112009.html 2017-01-19T10:58:19.220Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Submits-US-New-Drug-Application-for-Brilinta-19112009.html 2017-01-19T10:58:38.436Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Targacept-Form-Global-Collaboration-and-Licence-Agreement-03122009.html 2017-01-19T10:58:57.098Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-FDA-Approves-Seroquel-XR-For-AddOn-Treatment-Of-Major-Depressive-Disorder-04122009.html 2017-01-19T10:59:14.893Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-FDA-Approves-Seroquel-For-The-Paediatric-Treatment-04122009.html 2017-01-19T10:59:57.400Z https://www.astrazeneca.com/media-centre/press-releases/2009/Advisory-Committee-Briefing-Materials-For-Crestor-sND-11122009.html 2017-01-19T11:00:25.010Z https://www.astrazeneca.com/media-centre/press-releases/2009/Favourable-Vote-From-FDA-Advisory-Committee-On-Benefit-15122009.html 2017-01-19T11:00:57.050Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-To-Acquire-Infection-Research-Company-Novexel-23122009.html 2017-01-19T11:01:18.206Z https://www.astrazeneca.com/media-centre/press-releases/2009/MedImmune-Replies-to-FDA-Complete-Response-Letter-on-Motavizumab-24122009.html 2017-01-19T11:01:44.039Z https://www.astrazeneca.com/media-centre/articles.html 2018-04-27T11:04:00.337+01:00 https://www.astrazeneca.com/media-centre/articles/2017/revealing-the-dynamic-structure-of-atm.html 2017-05-11T08:05:24.351+01:00 https://www.astrazeneca.com/media-centre/articles/2017/compex-novel-exacerbation-measure-may-speed-up-asthma-drug-development-05062017.html 2017-06-05T06:22:55.867+01:00 https://www.astrazeneca.com/media-centre/articles/2017/switching-the-light-off-in-the-discovery-of-new-cancer-therapies-against-kras-15062017.html 2017-07-06T13:51:55.943+01:00 https://www.astrazeneca.com/media-centre/articles/2017/building-a-community-of-collaboration-in-genomic-science-14062017.html 2017-07-06T13:51:55.958+01:00 https://www.astrazeneca.com/media-centre/articles/2017/bahija-jallal-of-medimmune-and-mark-oconnor-of-astrazeneca-celeb.html 2017-07-07T13:47:59.104+01:00 https://www.astrazeneca.com/media-centre/articles/2017/understanding-the-many-costs-of-lupus.html 2017-07-06T13:51:55.938+01:00 https://www.astrazeneca.com/media-centre/articles/2017/imperial-college-research-collaboration-breaks-new-ground-for-dr.html 2017-07-07T13:34:24.295+01:00 https://www.astrazeneca.com/media-centre/articles/2017/noble-prize-inspiration-initiative-sir-tim-hunt-leads-program-in-germany-to-initiate-scientific-exchange-11072017.html 2017-07-19T18:00:37+01:00 https://www.astrazeneca.com/media-centre/articles/2017/finding-a-cancer-off-switch-for-mutant-ras-13072017.html 2017-07-14T14:39:27.246+01:00 https://www.astrazeneca.com/media-centre/articles/2017/dna-damage-response-at-WCSJ-2017.html 2017-07-26T18:38:25.752+01:00 https://www.astrazeneca.com/media-centre/articles/2017/mrc-opens-drug-discovery-funding-applications-to-work-with-nicol.html 2017-08-07T10:54:16.157+01:00 https://www.astrazeneca.com/media-centre/articles/2017/astrazeneca-and-medimmune-enter-strategic-collaboration-with-ethris-to-develop-mrna-therapies-for-respirator-diseases-17082017.html 2017-08-21T14:24:48.813+01:00 https://www.astrazeneca.com/media-centre/articles/2017/professor-shinya-yamanaka-to-inspire-young-scientists-and-students-in-oslo-and-gothenburg-in-two-day-nobel-prize-inspiration-initiative-event-01092017.html 2017-09-11T08:38:49.657+01:00 https://www.astrazeneca.com/media-centre/articles/2017/astrazeneca-appoints-professor-maria-belvisi-to-its-imed-biotech-unit-as-head-of-respiratory-inflammation-and-autoimmunity-08092017.html 2017-09-08T09:08:44.734+01:00 https://www.astrazeneca.com/media-centre/articles/2017/astrazeneca-again-recognised-as-global-sustainability-leader-19092017.html 2017-09-27T17:01:01.122+01:00 https://www.astrazeneca.com/media-centre/articles/2017/nobel-prize-in-chemistry-awarded-to-cryo-electron-microscopy--cr.html 2017-10-05T14:46:56.029+01:00 https://www.astrazeneca.com/media-centre/articles/2017/barcoding-crispr-cas9-improves-the-search-for-novel-drug-targets.html 2017-10-16T17:40:38.664+01:00 https://www.astrazeneca.com/media-centre/articles/2017/astrazeneca-together-with-partner-organisations-launch-2017-global-diabetes-policy-forum-for-action-in-diabetes-171017.html 2017-10-17T17:23:48.020+01:00 https://www.astrazeneca.com/media-centre/articles/2017/its-official-astrazeneca-and-medimmune-ranked-a-top-place-for-scientists-to-work-by-science-20102017.html 2017-10-20T11:57:51.632+01:00 https://www.astrazeneca.com/media-centre/articles/2017/new-research-reveals-missing-link-between-tumour-suppressors-and-prostate-cancer-191017.html 2017-10-19T18:44:57.347+01:00 https://www.astrazeneca.com/media-centre/articles/2017/bridging-the-gap-between-fundamental-computer-vision-research-and-drug-discovery23102017.html 2018-03-26T14:31:17.709+01:00 https://www.astrazeneca.com/media-centre/articles/2017/astrazeneca-achieves-top-ranking-for-environmental-leadership-in-climate-and-water-protection-24102017.html 2017-10-24T13:03:08.586+01:00 https://www.astrazeneca.com/media-centre/articles/2017/balancing-foxo1-inhibition-opens-up-a-new-target-in-diabetes-24102017.html 2017-10-25T17:35:18.554+01:00 https://www.astrazeneca.com/media-centre/articles/2017/a-new-analysis-of-the-changing-terminology-of-precision-medicine-26102017.html 2017-10-26T15:47:12.474+01:00 https://www.astrazeneca.com/media-centre/articles/2017/5-tips-to-create-a-movement-from-a-single-idea-09112017.html 2017-11-09T11:27:09.511Z https://www.astrazeneca.com/media-centre/articles/2017/directing-crispr-cas9-gene-editing-using-novel-guides20112017.html 2017-11-20T10:36:38.471Z https://www.astrazeneca.com/media-centre/articles/2017/specifying-the-role-of-the-immune-systems-sentry-guards-29112017.html 2017-12-04T11:46:00.506Z https://www.astrazeneca.com/media-centre/articles/2017/active-science-_-inspiring-the-next-generation-of-scientists-through-sports-30112017.html 2017-12-04T12:39:55.945Z https://www.astrazeneca.com/media-centre/articles/2017/mene-pangalos-awarded-honorary-doctor-of-science-for-commitment-to-life-sciences-04122017.html 2017-12-04T11:44:41.143Z https://www.astrazeneca.com/media-centre/articles/2017/kcc2-unlocking-the-secrets-of-over-excited-nerves-08122017.html 2017-12-08T16:28:12.663Z https://www.astrazeneca.com/media-centre/articles/2017/astrazeneca-and-imperial-college-london-establish-research-collaboration-to-investigate-biological-drivers-of-respiratory-disease-21122017.html 2017-12-21T10:57:32.759Z https://www.astrazeneca.com/media-centre/articles/2017/harnessing-the-power-of-genomics-through-global-collaborations-and-scientific-innovation-12012018.html 2018-01-12T13:12:57.879Z https://www.astrazeneca.com/media-centre/articles/2017/new-structural-insight-into-the-highly-challenging-drug-target-par2-helps-paves-the-way-for-future-therapies-in-inflammatory-pain.html 2017-04-27T06:23:20.659+01:00 https://www.astrazeneca.com/media-centre/articles/2018/new-research-paper-shows-that-astrazeneca-has-achieved-greater-than-four-fold-improvement-in-rd-productivity-19012018.html 2018-01-19T14:45:20.208Z https://www.astrazeneca.com/media-centre/articles/2018/harnessing-crispr-cas9-to-reverse-the-effects-of-a-harmful-genetic-mutation-in-an-animal-model.html 2018-03-05T06:52:16.317Z https://www.astrazeneca.com/media-centre/articles/2018/astrazeneca-and-lucy-cavendish-college-establish-women-in-science-and-leadership-mentoring-collaboration-26032018.html 2018-03-26T07:48:27.229+01:00 https://www.astrazeneca.com/media-centre/articles/2018/astrazeneca-recognised-as-most-innovative-pharma-company.html 2018-04-03T22:58:26.517+01:00 https://www.astrazeneca.com/media-centre/articles/2018/new-insight-into-the-underlying-biology-of-heart-failure.html 2018-04-17T16:53:31.378+01:00 https://www.astrazeneca.com/media-centre/articles/2018/earth-day-2018-astrazenecas-commitment-to-environmental-protection.html 2018-04-20T12:52:35.852+01:00 https://www.astrazeneca.com/media-centre/articles/2018/cambridge-life-sciences-cluster-set-to-deliver-an-additional-gbp1-billion-to-the-uk-economy-by-2032-03052018.html 2018-05-20T09:05:32.365+01:00 https://www.astrazeneca.com/media-centre/articles/2018/astrazeneca-partners-with-cambridge-institute-for-sustainability-leadership-to-launch-unique-sustainability-project-in-kenya.html 2018-05-21T07:23:21.427+01:00 https://www.astrazeneca.com/media-centre/articles/2018/astrazeneca-announces-opening-of-new-south-san-francisco-site-22052018.html 2018-05-22T17:54:58.600+01:00 https://www.astrazeneca.com/media-centre/articles/2018/meeting-the-future-together-astrazeneca-gothenburg-hosts-third-exchange-event-05062018.html 2018-06-05T15:26:37.641+01:00 https://www.astrazeneca.com/media-centre/articles/2018/preclinical-data-of-the-atm-inhibitor-azd1390-show-promising-results-in-brain-tumour-models.html 2018-06-21T13:01:38.517+01:00 https://www.astrazeneca.com/media-centre/articles/2016/Novel-approach-to-Chronic-Kidney-Disease-CKD-research-addresses-both-its-complications-and-underlying-causes.html 2017-07-06T13:51:55.961+01:00 https://www.astrazeneca.com/media-centre/medical-releases.html 2018-04-27T11:03:05.989+01:00 https://www.astrazeneca.com/media-centre/medical-releases/Arthritis-and-Rheumatology-publishes-positive-Phase-II-data-on-anifrolumab-in-lupus-14112016.html 2016-11-15T18:04:17.568Z https://www.astrazeneca.com/media-centre/medical-releases/durvalumab-monotherapy-demonstrates-efficacy-in-urothelial-bladder-cancer.html 2016-11-15T18:42:01.834Z https://www.astrazeneca.com/media-centre/medical-releases/astrazenecas-combination-of-durvalumab-with-tremelimumab-shows-clinical-activity-in-non-small-cell-lung-cancer-irrespective-of-pd-l1-status-cancer-0120160.html 2016-11-15T18:52:29.423Z https://www.astrazeneca.com/media-centre/medical-releases/durvalumab-shows-promising-preliminary-early-data-in-lung-and-head-and-neck-cancers-10102016.html 2016-11-15T18:43:31.042Z https://www.astrazeneca.com/media-centre/medical-releases/phase-iii-combination-trial-of-bydureon-and-forxiga-shows-signif.html 2016-11-11T20:42:54.895Z https://www.astrazeneca.com/media-centre/medical-releases/socrates-trial-results-for-brilinta-brilique-presented-at-europe.html 2016-11-11T20:42:55.300Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-two-new-phase-iiib-trials-for-forxiga-in-c.html 2016-11-11T20:42:55.617Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-receives-approval-in-the-eu-for-qtern--saxagliptin-a.html 2016-11-11T20:42:55.884Z https://www.astrazeneca.com/media-centre/medical-releases/positive-chmp-opinion-in-eu-for-saxa-dapa--saxagliptin-and-dapag.html 2016-11-11T20:42:56.203Z https://www.astrazeneca.com/media-centre/medical-releases/acalabrutinib-recommended-for-orphan-drug-designation-in-Europe-for-three-indications.html 2016-11-11T20:42:56.575Z https://www.astrazeneca.com/media-centre/medical-releases/Tagrisso-osimertinib-shows-clinical-activity-in-patients-with-leptomeningeal-disease-from-lung-cancer.html 2016-11-11T20:42:56.905Z https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-further-evidence-for-the-potential-of-AZD9291-in-first-line-and-pre-treated-non-small-cell-lung-cancer.html 2016-11-11T20:42:58.096Z https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-advances-in-oncology-research-at-ECC-2015-with-data-on-AZD9291-durvalumab-and-LYNPARZA-olaparib.html 2016-11-11T20:42:57.100Z https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-positive-Tagrisso-osimertinib-follow-up-data-in-lung-cancer-at-ELCC-2016.html 2016-11-11T20:42:57.334Z https://www.astrazeneca.com/media-centre/medical-releases/Lynparza-olaparib-latest-data-suggest-potential-overall-survival-advantage-in-patients-with-platinum-sensitive-ovarian-cancer.html 2016-11-11T20:42:57.553Z https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-to-present-anifrolumab-lupus-data-at-Annual-European-Congress-of-Rheumatology-EULAR-2016.html 2016-11-15T17:06:53.073Z https://www.astrazeneca.com/media-centre/medical-releases/euclid-trial-results-for-brilinta-brilique-presented-at-the-american.html 2016-11-15T19:27:32.157Z https://www.astrazeneca.com/media-centre/medical-releases/Early-data-demonstrate-clinical-activity-of-acalabrutinib-in-difficult-to-treat-chronic-lymphocytic-leukaemia-05122016.html 2016-12-05T15:24:47.501Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-supports-the-publication-of-the-2017-gold-strategy-for-improving-copd-diagnosis-management-and-prevention-09122016.html 2016-12-09T13:30:48.235Z https://www.astrazeneca.com/media-centre/medical-releases/US-FDA-approves-Symbicort-budesonide-formoterol-for-the-treatment-of-asthma-in-paediatric-patients-300120170.html 2017-01-30T11:01:13.026Z https://www.astrazeneca.com/media-centre/medical-releases/lynparza--olaparib--maintenance-treatment-offers-sustained-quality-of-life-alongside-improved-progression-free-survival-in-women-with-brca-mutated-ovarian-cancer-02072017.html 2017-06-02T07:05:39.352+01:00 https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-tagrisso-osimertinib-data-in-patients-with-egfr-t790m-mutation-positive-lung-cancer-and-central-nervous-system-metastases-06062017.html 2017-06-06T06:45:18.042+01:00 https://www.astrazeneca.com/media-centre/medical-releases/new-data-supports-long-term-efficacy-of-ticagrelor-in-patients-up-to-five-years-following-a-heart-attack-06092017.html 2017-09-06T14:24:20.742+01:00 https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-new-evidence-on-symbicort-budesonide-formoterol-in-copd-patients-at-risk-of-exacerbation.html 2017-09-10T00:31:25.598+01:00 https://www.astrazeneca.com/media-centre/medical-releases/forxiga-depict-1-trial-demonstrates-improved-glycaemic-control-without-increasing-hypoglycaemia-14092017.html 2017-09-14T07:55:36.733+01:00 https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-and-chi-meds-savolitinib-shows-encouraging-clinical-activity-in-2nd-line-egfr-mutation-positive-lung-cancer-with-met-amplification-171017.html 2017-10-31T20:08:48.994Z https://www.astrazeneca.com/media-centre/medical-releases/zs-9-sodium-zirconium-cyclosilicate-phase-iii-long-term-safety-and-efficacy-data-presented-at-asn-kidney-week-201702112017.html 2017-11-02T12:55:31.338Z https://www.astrazeneca.com/media-centre/medical-releases/faslodex-fulvestrant-receives-eu-approval-for-the-treatment-of-hormone-receptor-positive-advanced-breast-cancer-in-combination-with-palbociclib-14112017.html 2017-11-14T15:45:36.567Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-show-benefit-of-tagrisso-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-and-central-nervous-system-metastases-20112017.html 2017-11-20T10:45:21.573Z https://www.astrazeneca.com/media-centre/medical-releases/new-england-journal-of-medicine-publishes-results-of-phase-iii-flaura-trial-in-the-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-20112017.html 2017-11-20T10:34:45.994Z https://www.astrazeneca.com/media-centre/medical-releases/risk-of-repeat-heart-attack-twice-as-likely-from-occlusions-in-arteries-that-did-not-cause-initial-event.html 2018-01-11T14:46:31.437Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-enrols-first-patient-in-new-brilinta-ticagrelor-stroke-trial-23012018.html 2018-01-24T13:59:59.198Z https://www.astrazeneca.com/media-centre/medical-releases/brilinta-meets-primary-endpoint-in-phase-iii-thrombolysis-trial.html 2018-03-12T11:02:14.268Z https://www.astrazeneca.com/media-centre/medical-releases/brilinta-ticagrelor-associated-with-a-reduction-in-risk-for-cardiovascular-events-versus-clopidogrel-in-heart-attack-survivors-with-moderate-kidney-disease-090418.html 2018-04-09T09:20:31.085+01:00 https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-imfinzi-durvalumab-plus-tremelimumab-combination-data-at-aacr-annual-meeting-170418.html 2018-04-17T12:56:07.651+01:00 https://www.astrazeneca.com/media-centre/image-and-broadcast-library.html 2018-03-07T22:04:38.580Z https://www.astrazeneca.com/media-centre/Broadcast.html 2018-01-24T16:46:15.820Z https://www.astrazeneca.com/media-centre/archive.html 2018-01-24T16:43:56.416Z https://www.astrazeneca.com/sustainability.html 2018-04-09T19:04:23.113+01:00 https://www.astrazeneca.com/sustainability/access-to-healthcare.html 2018-03-09T15:07:19.570Z https://www.astrazeneca.com/sustainability/access-to-healthcare/healthy-heart-africa.html 2018-03-05T17:40:01.700Z https://www.astrazeneca.com/sustainability/access-to-healthcare/young-health-programme.html 2018-03-05T10:18:27.929Z https://www.astrazeneca.com/sustainability/access-to-healthcare/healthy-lung-asia.html 2018-06-11T13:45:39.518+01:00 https://www.astrazeneca.com/sustainability/environmental-protection.html 2018-05-30T13:09:19.030+01:00 https://www.astrazeneca.com/sustainability/environmental-protection/ghg-and-energy-management.html 2018-03-06T08:36:49.772Z https://www.astrazeneca.com/sustainability/environmental-protection/pharmaceuticals-in-the-environment.html 2018-03-05T17:40:01.699Z https://www.astrazeneca.com/sustainability/environmental-protection/manufacturing-and-the-environment.html 2018-03-05T17:44:04.903Z https://www.astrazeneca.com/sustainability/ethics-and-transparency.html 2018-06-18T19:58:26.480+01:00 https://www.astrazeneca.com/sustainability/ethics-and-transparency/astrazeneca-and-global-transparency.html 2018-05-09T17:49:09.625+01:00 https://www.astrazeneca.com/sustainability/resources.html 2018-05-31T14:39:12.414+01:00 https://www.astrazeneca.com/sustainability/community-investment.html 2018-03-06T09:31:29.107Z https://www.astrazeneca.com/sustainability/sustainability-foundations.html 2018-03-20T11:25:07.830Z https://www.astrazeneca.com/careers.html 2018-06-15T12:12:06.999+01:00 https://www.astrazeneca.com/investor-relations.html 2018-06-21T09:35:18.053+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/asco-ir-event.html 2017-03-07T07:07:23.207Z https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-h1-2016-results.html 2017-03-07T07:07:16.933Z https://www.astrazeneca.com/investor-relations/IR-archive/AstraZeneca-Q1-2016-Results.html 2017-03-07T07:07:13.381Z https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-year-to-date-and-q3-2017-results.html 2018-02-02T06:31:05.296Z https://www.astrazeneca.com/investor-relations/IR-archive/full-year-and-q4-2016-results.html 2017-04-20T12:48:51.426+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-q1-2017-results.html 2017-05-02T17:04:07.794+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/year-to-date-and-q3-2016-results.html 2017-12-19T11:08:14.886Z https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-h1-2017-results.html 2018-01-04T10:34:24.425Z https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-year-to-date-and-q3-2015-results.html 2017-07-06T13:56:48.546+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-FY-2015-results.html 2017-05-04T13:00:41.845+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/invitation-second-year-end-late-stage-pipeline-investor-science.html 2017-03-07T07:06:17.816Z https://www.astrazeneca.com/investor-relations/IR-archive/Majority-stake-in-Acerta-Pharma-Investor-conference-call-replay.html 2017-03-07T07:06:26.828Z https://www.astrazeneca.com/investor-relations/IR-archive/Conference-call-AstraZeneca-strengthens-Cardiovascular-and-Metabolic-disease-portfolio-06112015.html 2017-03-07T07:06:34.666Z https://www.astrazeneca.com/investor-relations/IR-archive/american-college-of-rheumatology.html 2017-03-07T07:06:38.393Z https://www.astrazeneca.com/investor-relations/IR-archive/investor-science-conference-call.html 2017-05-04T12:36:05.984+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/late-stage-pipeline-call.html 2017-05-04T12:39:22.229+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/for-investors.html 2017-07-13T12:47:13.733+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-investor-science-event-at-esmo-2017.html 2017-09-13T11:38:44.204+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-investor-science-event-at-ers-2017.html 2017-09-14T08:15:52.742+01:00 https://www.astrazeneca.com/investor-relations/IR-archive/investor-science-event-late-stage-pipeline-webcast.html 2017-12-20T13:45:06.873Z https://www.astrazeneca.com/investor-relations/IR-archive/astrazeneca-full-year-2017-results.html 2018-02-02T13:21:48.179Z https://www.astrazeneca.com/investor-relations/AGMwebcast2018.html 2018-04-13T11:39:37.411+01:00 https://www.astrazeneca.com/investor-relations/astrazeneca-adr-programme.html 2018-03-07T00:05:32.005Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements.html 2017-08-14T16:07:02.416+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-completes-global-licencing-agreement-with-LEO-Pharma-for-tralokinumab-160820161.html 2017-02-17T06:40:59.141Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-to-sell-small-molecule-antibiotics-business-to-Pfizer-24082016.html 2017-01-11T17:09:29.208Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-enters-licensing-agreements-with-LEO-Pharma-in-skin-diseases.html 2016-11-11T18:41:02.588Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-enters-into-agreement-to-resolve-Faslodex-patent-litigation-in-the-US-13072016.html 2016-11-11T18:41:03.016Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Tagrisso-met-primary-endpoint-in-phase-III-2nd-line-lung-cancer-trial-18072016.html 2017-01-11T17:15:52.987Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-receives-approval-in-the-EU-for-Qtern-saxagliptin-and-dapagliflozin-for-treatment-of-Type-2-diabetes-19072016.html 2017-01-11T17:14:57.302Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/h1-2016-results.html 2017-01-11T17:13:32.506Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-provides-update-on-Phase-III-trial-of-Selumetinib-in-non-small-cell-lung-cancer-09082016.html 2017-01-11T17:12:16.126Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-announces-investment-in-Moderna-10082016.html 2017-01-11T17:11:35.141Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/change-to-astrazeneca-board-of-directors-28092016.html 2017-01-11T17:01:32.959Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/medimmune-out-licenses-potential-medicine-for-inflammatory-diseases-to-allergan-03102016.html 2017-01-11T17:00:51.098Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-reports-top-line-results-from-the-brilinta-euclid-trial-in-patients-with-peripheral-artery-disease-04102016.html 2017-01-11T16:59:13.390Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-enters-agreement-with-aralez-for-beta-blocker-medicine-in-the-us-04102016.html 2017-01-11T16:57:18.993Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-enters-agreement-with-cilag-gmbh-international-to-divest-rights-to-rhinocort-aqua-outside-the-us-071020161.html 2017-01-11T16:56:53.223Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/fda-accepts-for-review-new-drug-application-for-sodium-zirconium-18102016.html 2016-11-11T18:41:08.319Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-phase-iii-solo-2-trial-shows-significant-progression-free-survival-benefit-261020161.html 2016-11-11T19:26:34.420Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-completes-agreement-with-Aralez-for-beta-blocker-medicine-Toprol-XL-in-the-US-31102016.html 2016-11-11T18:41:09.504Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-head-and-neck-cancer-trials-27102016.html 2016-11-11T18:41:09.929Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Transparency-Directive-Voting-Rights-and-Capital-01082016.html 2016-11-11T18:41:10.425Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Transaction-by-Person-Discharging-Managerial-Responsibilities-Disclosure-Rule-DTR-3-1-4-01082016.html 2016-11-11T18:41:10.930Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Transparency-Directive-Voting-Rights-and-Capital-01112016.html 2016-11-11T18:41:11.386Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Transaction-by-Person-Closely-Associated-with-a-Person-Discharging-Managerial-Responsibilities-01112016.html 2016-11-11T18:41:12.104Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Transparency-Directive-Voting-Rights-and-Capital-01092016.html 2016-11-11T18:41:12.560Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Transparency-Directive-Voting-Rights-and-Capital-03102016.html 2016-11-11T18:41:13.059Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/New-external-board-appointment-18082016.html 2016-11-11T18:41:13.808Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/New-external-board-appointment-22092016.html 2016-11-11T18:41:14.192Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Transaction-by-Person-Discharging-Managerial-Responsibilities-Disclosure-Rule-DTR-3-1-4-26092016.html 2016-11-11T18:41:14.936Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Notice-of-results-27072016.html 2017-04-21T13:27:04.792+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/AstraZeneca-completes-commercialisation-agreement-with-Aspen-for-anaesthetics-portfolio-01092016.html 2016-11-11T18:41:16.007Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/change-to-astrazeneca-board-of-directors-09112016.html 2016-11-11T18:41:16.609Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Q3-2016-results.html 2016-12-14T14:59:19.641Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/MedImmune-completes-out-licensing-agreement-with-Allergan-for-MEDI2070-17112016.html 2016-11-17T07:19:58.215Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-head-and-neck-cancer-trials-resume-new-patient-enrolment-as-fda-lifts-partial-clinical-hold-22112016.html 2016-11-22T07:13:00.915Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01122016.html 2016-12-01T14:49:10.973Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-completes-agreement-with-cilag-gmbh-international-for-rights-to-rhinocort-aqua-outside-the-us-05122016.html 2016-12-05T05:56:34.998Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/tagrisso-demonstrates-superiority-over-chemotherapy-in-egfr-t790m-mutation-positive-non-small-cell-lung-cancer-06122016.html 2017-07-06T13:56:48.527+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/US-FDA-accepts-first-biologics-license-application-for-AstraZenecas-durvalumab-in-bladder-cancer09122012.html 2016-12-09T15:40:16.956Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Block-listing-six-monthly-return-12122016.html 2016-12-13T17:23:08.681Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transaction-by-a-person-discharging-managerial-responsibilities-161220161.html 2016-12-16T13:23:21.179Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-completes-sale-of-small-molecule-antibiotics-business-to-pfizer-23122016.html 2016-12-22T15:06:30.306Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-03012017.html 2017-01-03T15:52:51.436Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-programme-opportunities-17012017.html 2017-01-17T06:16:48.328Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/year-to-date-and-q4-2016-results-02022017.html 2017-02-10T13:54:04.175Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/symbicort-granted-paediatric-exclusivity-in-the-us-26012017.html 2017-01-26T09:50:31.303Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/Transparency-Directive-Voting-Rights-and-Capital-01022017.html 2017-02-01T14:48:58.705Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/siliq-brodalumab-approved-by-the-US-FDA-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-16022017.html 2017-02-16T11:36:48.301Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-meets-primary-endpoint-in-phase-iii-trial-in-brca-mutated-metastatic-breast-cancer-17022017.html 2017-02-17T06:42:48.520Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-enters-agreement-with-tersera-therapeutics-for-zoladex-in-the-us-and-canada-20022017.html 2017-02-20T06:33:13.561Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/zs-9-sodium-zirconium-cyclosilicate-receives-positive-chmp-opinion-for-the-treatment-of-hyperkalaemia-24022017.html 2017-03-03T06:32:25.976Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/fda-approves-once-daily-qtern-dapagliflozin-and-saxagliptin-tablets-for-adults-with-type-2-diabetes-240217.html 2017-02-28T06:33:05.893Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01032017.html 2017-03-02T15:19:58.920Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/medimmune-and-sanofi-pasteur-form-alliance-to-develop-and-commercialise-potential-next-generation-respiratory-syncytial-virus-antibody-medi8897-03032017.html 2017-03-03T06:43:07.670Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/changes-to-astrazeneca-board-of-directors-06032017.html 2017-03-06T08:18:08.067Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/annual-financial-report-07032017.html 2017-03-07T16:23:10.698Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/filing-of-annual-report-on-form-20-f-with-the-us-securities-and-exchange-commission.html 2017-03-08T14:59:35.763Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-phase-iii-solo-2-data-demonstrate-progression-free-survival-benefit-in-brca-mutated-ovarian-cancer-as-maintenance-therapy-15032017.html 2017-03-14T19:03:30.468Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/notice-of-annual-general-meeting-16032017.html 2017-03-16T10:10:05.765Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-receives-complete-response-letter-from-us-fda-for-zs-sodium-zirconium-cyclosilicate-for-hyperkalaemia-17032017.html 2017-03-17T07:07:44.399Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transactions-by-persons-discharging-managerial-responsibilities-27032017.html 2017-03-27T19:22:31.075+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transactions-by-persons-discharging-managerial-responsibilities-28032017.html 2017-03-29T11:48:31.150+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-completes-agreement-with-tersera-therapeutics-for-commercial-rights-to-zoladex-in-the-us-and-canada-31032017.html 2017-03-31T06:41:25.503+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/tagrisso-osimertinib-receives-us-fda-full-approval-31032017.html 2017-03-31T07:04:42.927+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital.html 2017-04-03T15:21:54.777+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/tagrisso-receives-full-approval-in-the-eu-25042017.html 2017-04-25T13:36:07.259+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/q1-2017-results.html 2017-05-02T13:13:25.391+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/results-of-annual-general-meeting-held-on-27-april-2017-270417.html 2017-04-28T12:43:03.718+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazenecas-imfinzi-durvalumab-receives-us-fda-accelerated-approval-for-previously-treated-patients-with-advanced-bladder-cancer-01052017.html 2017-05-08T10:38:28.400+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-02052017.html 2017-05-02T16:57:10.989+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-provides-update-on-stratos-1-phase-iii-trial-of-tralokinumab-in-severe-uncontrolled-asthma.html 2017-05-10T07:16:29.402+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/imfinzi-significantly-reduces-the-risk-of-disease-worsening-or-death-in-the-phase-iii-pacific-trial-for-stage-iii-unresectable-lung-cancer-12052017.html 2017-05-12T06:56:32.123+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-pdmr-shareholding.html 2017-05-16T15:28:14.143+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-enters-agreement-with-recordati-for-seloken-in-europe-22052017.html 2017-05-22T07:33:22.467+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html 2017-05-23T07:35:41.170+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-pdmr-shareholding-24052017.html 2017-05-24T17:18:02.656+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/directorate-change-31052017.html 2017-05-31T06:22:10.715+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-significantly-reduces-the-risk-of-disease-worsening-or-death-in-patients-with-BRCA-mutated-metastatic-breast-cancer-05062017.html 2017-06-04T21:39:16.508+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-prices-a-2bn-bond-issue-06062017.html 2017-06-06T07:03:22.506+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-enters-agreement-with-grunenthal-to-divest-rights-to-migraine-treatment-zomig-07062017.html 2017-06-07T07:24:52.259+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/faslodex-fulvestrant-receives-positive-chmp-opinion-for-use-in-1st-line-hormone-receptor-positive-advanced-breast-cancer-23062017.html 2017-06-23T13:01:28.676+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01062017.html 2017-06-30T12:07:38.497+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/block-listing-six-monthly-return-01062017.html 2017-06-30T12:07:56.674+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-completes-agreement-with-recordati-for-seloken-in-europe-03072017.html 2017-07-03T06:23:58.954+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-completes-divestment-agreement-with-grunenthal-for-migraine-treatment-zomig-03072017.html 2017-07-03T06:24:23.031+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-03072017.html 2017-07-04T09:54:08.878+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/faslodex-receives-eu-approval-as-first-line-therapy-for-advanced-breast-cancer-26072017.html 2017-07-26T17:44:15.361+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/h1-2017-results.html 2017-08-01T15:03:29.366+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-and-merck-establish-strategic-oncology-collaboration-27072017.html 2017-07-27T07:16:39.772+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html 2017-07-27T06:48:46.821+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/tagrisso-significantly-improves-progression-free-survival-in-the-phase-iii-flaura-trial-for-lung-cancer-27072017.html 2017-07-27T06:55:02.126+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-pdmr-shareholding-28072017.html 2017-07-28T11:33:51.539+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/imfinzi-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-locally-advanced-unresectable-non-small-cell-lung-cancer-31072017.html 2017-08-02T14:05:45.047+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma-01082017.html 2017-08-01T07:09:06.089+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01082017.html 2017-08-01T13:29:35.532+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-accepts-regulatory-submission-for-acalabrutinib-and-grants-priority-review-02082017.html 2017-08-02T06:56:40.744+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/publication-of-prospectus-10082017.html 2017-08-10T13:30:44.821+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/holding-in-company-21072017.html 2017-08-14T16:19:43.323+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-non-executive-director-retirement-16082017.html 2017-08-16T06:12:36.285+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-receives-additional-and-broad-approval-in-the-us-for-ovarian-cancer.html 2017-08-17T21:17:19.824+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-breast-cancer-28082017.html 2017-08-29T06:27:15.008+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01092017.html 2017-09-01T14:56:55.982+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/directorate-change-05092017.html 2017-09-04T15:19:23.415+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients-with-severe-uncontrolled-asthma-06092017.html 2017-09-07T06:02:02.535+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/duaklir-significantly-improves-lung-function-in-copd-patients-07092017.html 2017-09-07T06:46:29.461+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/celgene-and-astrazeneca-provide-update-on-the-fusion-clinical-trial-programme-07092017.html 2017-09-07T13:02:50.293+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-tagrisso-shows-potential-as-a-new-standard-of-care-in-1st-line-egfr-mutated-lung-cancer-at-esmo-2017-congress-11092017.html 2017-09-11T05:57:32.320+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-11092017.html 2017-09-11T06:03:07.648+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-and-aspen-enter-agreement-for-remaining-rights-to-anaesthetics-medicines14092017.html 2017-09-14T06:14:25.053+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-pdmr-shareholding-260917.html 2017-09-26T11:45:53.943+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-02102017.html 2017-10-02T14:47:18.053+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/tagrisso-granted-breakthrough-therapy-designation-by-us-fda-for-the-1st-line-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-09102017.html 2017-10-09T06:41:03.784+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-171017.html 2017-10-17T06:37:22.993+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-accepts-regulatory-submission-for-lynparza-in-metastatic-breast-cancer-and-grants-priority-review-18102017.html 2017-10-18T07:07:26.606+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes-231017.html 2017-10-22T22:37:37.130+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-and-msd-rapidly-advance-lynparza-in-japan-with-a-second-regulatory-submission-231017.html 2017-10-23T07:11:15.156+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html 2017-10-31T17:49:03.619Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-and-aspen-complete-agreement-for-residual-rights-to-anaesthetic-medicines31102017.html 2017-10-31T18:38:30.436Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-provides-update-on-tralokinumab-phase-iii-programme-in-severe-uncontrolled-asthma-01112017.html 2017-11-01T06:16:53.521Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01112017.html 2017-11-01T14:37:34.628Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/year-to-date-and-q3-2017-results.html 2018-02-23T07:23:17.981Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/benralizumab-receives-positive-eu-chmp-opinion-for-severe-uncontrolled-eosinophilic-asthma-10112017.html 2018-04-30T09:54:18.064+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html 2017-11-15T06:56:31.144Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/the-european-medicines-agency-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-24112017.html 2017-11-28T06:06:28.369Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-makes-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-in-japan-27112017.html 2017-11-27T06:23:21.023Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01122017.html 2017-12-01T15:02:20.426Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/block-listing-return-01122017.html 2017-12-01T15:05:59.577Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transaction-by-person-discharging-managerial-responsibilities-disclosure-under-article-19-of-the-eu-market-abuse-regulation-15122017.html 2018-02-23T07:31:40.838Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-18122017.html 2018-02-23T07:30:28.216Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-pdmr-shareholding-281217.html 2017-12-28T11:46:48.996Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-02012018.html 2018-01-02T12:44:28.389Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma-10012018.html 2018-02-23T07:28:42.973Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-12012018.html 2018-02-23T07:26:49.386Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-receives-approval-in-japan-for-the-treatment-of-advanced-ovarian-cancer-19012018.html 2018-01-18T22:10:29.095Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/fasenra-receives-approval-in-japan-19012018.html 2018-01-19T06:50:11.511Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-reports-top-line-phase-iii-kronos-trial-results-for-pt010-triple-combination-therapy-in-chronic-obstructive-pulmonary-disease-26012018.html 2018-02-23T07:25:41.528Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01022018.html 2018-02-01T12:54:13.245Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/full-year-2017-results.html 2018-02-23T07:24:03.283Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-pdmr-shareholding-05022018.html 2018-02-05T12:49:22.205Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/selumetinib-granted-orphan-drug-designation-by-the-us-fda-for-neurofibromatosis-type-1-15022018.html 2018-02-15T06:54:29.930Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer-19022018.html 2018-02-23T07:10:12.859Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-receives-positive-eu-chmp-opinion-in-platinum-sensitive-relapsed-ovarian-cancer-23022018.html 2018-02-23T12:25:21.194Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01032018.html 2018-03-01T13:56:34.867Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/annual-financial-report-06032018.html 2018-03-06T11:17:37.201Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/filing-of-annual-report-on-form-20-f-with-the-us-securities-and-exchange-commission-07032018.html 2018-03-07T06:17:01.658Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-provides-update-on-mystic-trial-timeline-12032018.html 2018-03-12T06:35:34.724Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lokelma-approved-in-the-eu-for-the-treatment-of-adults-with-hyperkalaemia-22032018.html 2018-03-22T16:56:58.985Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transactions-by-persons-discharging-managerial-responsibilities-26032018.html 2018-03-26T13:25:21.009+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transactions-by-persons-discharging-managerial-responsibilities-28032018.html 2018-03-28T13:37:30.439+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-03042018.html 2018-04-03T07:02:11.906+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-03042018.html 2018-04-03T06:42:46.455+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-030418.html 2018-04-03T14:18:09.011+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/directorate-change-050418.html 2018-04-04T18:31:41.073+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/notice-of-annual-general-meeting-13042018.html 2018-04-13T10:25:22.152+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-approves-tagrisso-as-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-19042018.html 2018-04-19T16:42:10.806+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-non-small-cell-lung-cancer24042018.html 2018-04-24T06:16:16.632+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/tagrisso-receives-positive-eu-chmp-opinion-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer27042018.html 2018-04-27T12:36:51.605+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer08052018.html 2018-05-08T11:22:10.050+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital01052018.html 2018-05-01T13:48:56.743+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-declaration-04052018.html 2018-05-04T11:32:14.847+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-and-luye-pharma-group-enter-agreement-for-rights-to-seroquel-and-seroquel-xr-in-the-uk-china-and-othe-international-markets.html 2018-05-08T15:48:09.351+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-11052018.html 2018-05-10T18:53:31.265+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/q1-2018-results.html 2018-05-18T07:21:36.168+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/results-of-annual-general-meeting-held-on-18-may-2018.html 2018-05-18T17:36:45.974+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/regulatory-submission-in-japan-for-forxiga-in-type-1-diabetes-21052018.html 2018-05-20T23:17:04.684+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html 2018-05-21T07:08:43.183+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018.html 2018-05-25T06:33:17.429+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-30052018.html 2018-05-30T05:55:02.153+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-declaration01062018.html 2018-06-01T10:59:52.547+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/block-listing-interim-review-01062018.html 2018-06-01T12:37:19.456+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/transparency-directive-voting-rights-and-capital-01062018.html 2018-06-01T12:39:26.223+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/director-declaration-08062018.html 2018-06-07T18:47:55.339+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/the-eu-approves-tagrisso-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-08062018.html 2018-06-08T17:39:11.797+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html 2018-06-12T06:38:41.990+01:00 https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/publication-of-prospectus-21062018.html 2018-06-21T23:05:11.743+01:00 https://www.astrazeneca.com/investor-relations/results-and-presentations.html 2018-06-21T09:35:50.635+01:00 https://www.astrazeneca.com/investor-relations/annual-reports.html 2018-03-06T06:50:21.947Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015.html 2017-04-21T13:45:51.045+01:00 https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/cautionary-statement.html 2017-02-27T14:22:30.013Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/reader-information.html 2017-04-21T13:45:51.043+01:00 https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/contact-information.html 2017-02-15T10:16:47.190Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016.html 2017-04-21T13:45:51.046+01:00 https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/contact-information.html 2017-03-02T13:14:01.195Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/annual-report-and-cautionary-statement.html 2017-03-03T09:05:22.380Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2017.html 2018-04-13T10:36:51.904+01:00 https://www.astrazeneca.com/investor-relations/corporate-governance.html 2018-03-28T18:54:01.488+01:00 https://www.astrazeneca.com/investor-relations/dividend-policy.html 2018-05-11T13:53:28.130+01:00 https://www.astrazeneca.com/investor-relations/debt-investors.html 2018-06-22T10:52:30.975+01:00 https://www.astrazeneca.com/investor-relations/shareholder-information.html 2018-06-07T10:19:38.353+01:00 https://www.astrazeneca.com/investor-relations/key-facts.html 2018-06-06T14:12:37.579+01:00 https://www.astrazeneca.com/investor-relations/faqs.html 2018-05-02T10:27:41.209+01:00 https://www.astrazeneca.com/investor-relations/events.html 2018-06-06T14:10:17.847+01:00 https://www.astrazeneca.com/investor-relations/astrazeneca-q1-2018-results.html 2018-05-18T15:06:38.935+01:00 https://www.astrazeneca.com/investor-relations/asco-2018-annual-meeting-investor-and-analyst-information.html 2018-06-08T11:53:49.828+01:00 https://www.astrazeneca.com/testing.html 2017-10-26T16:53:33.940+01:00 https://www.astrazeneca.com/Partnering.html 2018-03-26T10:48:01.142+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies.html 2018-02-02T10:27:44.566Z https://www.astrazeneca.com/Partnering/partnering-case-studies/agreement-with-china-medical-system-holdings-for-felodipine-plendil-in-china.html 2017-07-26T18:15:15.752+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/agreement-with-leo-pharma-for-potential-dermatology-medicines.html 2017-07-26T18:15:09.296+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/supporting-entrepreneurship-and-innovation.html 2018-04-26T19:38:24.249+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/Charles-River.html 2017-07-18T09:54:45.639+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/karolinska-institute.html 2018-05-14T10:08:50.006+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/glazgo-discovery-centre.html 2017-07-18T10:02:18.217+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/chi-med.html 2018-05-14T10:07:43.465+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/definiens.html 2016-09-08T17:08:33.554+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/guangzhou-medical-university-astrazeneca.html 2017-07-18T10:04:28.187+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/heptares.html 2017-07-18T10:05:34.220+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/pharmacyclics.html 2017-01-12T11:36:16.190Z https://www.astrazeneca.com/Partnering/partnering-case-studies/x-chem.html 2017-07-18T10:07:33.168+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/mrc.html 2017-07-18T10:08:38.863+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/horizon-discovery.html 2017-07-18T10:10:11.579+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/manchester-collaborative-centre-for-inflammation-research.html 2018-05-14T10:08:24.610+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/pharmaron.html 2017-07-18T10:12:35.482+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/petrov-institute.html 2017-07-18T10:13:42.754+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/vanderbilt.html 2018-05-14T10:11:00.224+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/university-of-virginia-and-astrazeneca-bench-to-bedside.html 2017-07-18T10:16:07.138+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/Joining-forces-withacademia-to-discover-novel-chemistry-approaches.html 2017-07-18T09:58:37.792+01:00 https://www.astrazeneca.com/Partnering/partnering-case-studies/collaborating-to-bring-personalised-treatments-to-cancer-patients.html 2017-03-08T16:03:27.060Z https://www.astrazeneca.com/Partnering/get-in-touch.html 2018-01-09T16:37:48.436Z https://www.astrazeneca.com/Partnering/externally-sponsored-scientific-research.html 2018-06-21T13:49:46.765+01:00 https://www.astrazeneca.com/Partnering/Externally-sponsored-scientific-research-training-centre.html 2017-12-06T16:01:37.175Z https://www.astrazeneca.com/terms-and-conditions.html 2018-06-05T12:59:02.483+01:00 https://www.astrazeneca.com/what-science-can-do.html 2018-06-12T07:30:20.413+01:00 https://www.astrazeneca.com/what-science-can-do/transforming-astrazenecas-rd-productivity-truth-seeking-curiosity-and-scientific-rigour.html 2018-01-19T08:52:29.211Z https://www.astrazeneca.com/what-science-can-do/transforming-astrazenecas-rd-productivity-truth-seeking-curiosity-and-scientific-rigour/5r-article-chapter-3-infographic.html 2018-01-19T08:57:05.933Z https://www.astrazeneca.com/what-science-can-do/transforming-astrazenecas-rd-productivity-truth-seeking-curiosity-and-scientific-rigour/5r-combined-infographic.html 2018-01-19T08:51:27.388Z https://www.astrazeneca.com/what-science-can-do/precision-medicine-and-genomics-targeting-innovative-medicines-to-patients-most-likely-to-benefit.html 2017-11-21T14:05:58.383Z https://www.astrazeneca.com/what-science-can-do/drug-modalities.html 2018-02-27T08:59:31.487Z https://www.astrazeneca.com/what-science-can-do/drug-modalities/modified-rna.html 2018-01-19T12:53:21.337Z https://www.astrazeneca.com/what-science-can-do/drug-modalities/protacs.html 2018-01-19T12:57:28.721Z https://www.astrazeneca.com/what-science-can-do/drug-modalities/small-molecule.html 2018-01-19T13:03:01.940Z https://www.astrazeneca.com/what-science-can-do/drug-modalities/bicyclic-peptides.html 2018-01-19T13:09:58.566Z https://www.astrazeneca.com/what-science-can-do/drug-modalities/therapeutic-proteins.html 2018-01-19T13:14:10.660Z https://www.astrazeneca.com/what-science-can-do/drug-modalities/antisense-oligonucleotides.html 2018-01-19T13:17:30.356Z https://www.astrazeneca.com/what-science-can-do/drug-modalities/oligonucleotide-conjugates.html 2018-01-19T13:20:25.761Z https://www.astrazeneca.com/what-science-can-do/drug-modalities/anticalins.html 2018-02-03T13:19:16.649Z https://www.astrazeneca.com/what-science-can-do/colab-high-throughput-screening-system.html 2017-07-06T14:59:29.618+01:00 https://www.astrazeneca.com/what-science-can-do/confocal-microscopy.html 2018-01-16T06:25:31.169Z https://www.astrazeneca.com/what-science-can-do/Acoustic-mass-spec.html 2017-07-06T14:59:29.629+01:00 https://www.astrazeneca.com/what-science-can-do/our-technology.html 2018-01-18T08:46:33.376Z https://www.astrazeneca.com/what-science-can-do/cardiac-regeneration.html 2018-03-26T10:48:01.148+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog.html 2018-05-18T12:20:27.996+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/autoimmunity/at-the-forefront-of-research-in-lupus.html 2017-11-02T15:20:15.734Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/autoimmunity/low-disease-activity-and-remission-in-sle-an-update.html 2018-03-20T18:06:21.477Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/autoimmunity/the-invisible-burdens-of-lupus.html 2018-03-20T18:24:05.824Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/cardiovascular.html 2015-12-21T09:38:04.777Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/cardiovascular/early-intervention-for-pre-diabetes-shown-to-prevent-long-term-complications.html 2017-07-06T14:28:57.387+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/cardiovascular/cardiovascular-disease-and-adherence-to-guidelines.html 2017-08-29T15:58:05.450+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/cardiovascular/the-patient-journey-in-secondary-prevention.html 2017-10-25T12:07:20.720+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/cardiovascular/asn-2017-bridging-astrazenecas-expertise-in-cardiovascular-and-metabolic-diseases-to-renal-risks-and-outcomes-30102017.html 2017-11-01T12:22:07.742Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/cardiovascular/recent-successes-and-future-opportunities-in-secondary-prevention-27112017.html 2017-11-29T11:30:52.089Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/cardiovascular/secondary-prevention-of-recurrent-atherothrombotic-events-among-high-risk-patients-17012018.html 2018-01-17T11:29:02.416Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/cardiovascular/from-cvmd-to-cvrm-bringing-renal-into-focus-in-our-approach-to-cardiovascular-renal-and-metabolism-09032018.html 2018-03-22T17:28:31.385Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology.html 2015-12-21T14:34:39.493Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/ovarian-cancer-towards-improved-quality-of-life-during-treatment-01062017.html 2017-07-06T14:28:57.443+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/an-interview-with-advocacy-01062017.html 2017-07-06T14:28:57.359+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/understanding-the-unmet-needs-of-women-with-brcam-breast-cancer-02062017.html 2017-07-06T14:28:57.430+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/Following%2520the%2520science%2520in%2520lung%2520cancer%2520to%2520address%2520the%2520hardest-to-treat%2520conditions.html 2017-07-06T14:28:57.408+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/single-molecule-science--at-the-frontier-of-drug-discovery-07062017.html 2017-06-30T12:01:52.552+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/a-renaissance-in-lung-cancer-research.html 2017-10-16T13:25:24.221+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/advocating-for-access-an-interview-with-lung-cancer-canadas-christina-sit-16102017.html 2017-10-16T16:53:26.093+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/are-accelerated-approval-mechanisms-a-predictor-to-early-access-08112017.html 2017-11-08T11:31:47.251Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/understanding-endpoints-in-cancer-research-13042018.html 2018-04-13T11:35:33.313+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/oncology/showcasing-our-ambition-in-oncology-at-the-2018-asco-annual-meeting01062018.html 2018-06-04T06:47:19.847+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/gastrointestinal.html 2015-12-22T13:12:08.688Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/respiratory.html 2016-01-15T09:48:50.950Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/respiratory/lets-talk-about-severe-asthma-05092017.html 2018-04-26T10:59:48.439+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/infectious-disease.html 2016-01-15T09:59:41.871Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/infectious-disease/launching-an-eu-manifesto-on-influenza-vaccination.html 2018-04-06T17:23:21.303+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/collaboration.html 2016-01-18T10:35:50.967Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/collaboration/ecodrug--a-database-connecting-drugs-and-conservation-of-their-targets-across-species-27112017.html 2017-12-01T09:28:00.361Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/neuroscience.html 2016-01-19T15:37:00.723Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/neuroscience/collaborating-to-advance-the-science-in-alzheimers-disease-14072017.html 2017-07-14T17:18:04.491+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/neuroscience/astrazenecas-commitment-to-neuroscience-research-on-world-alzheimers-day-2017-20092017.html 2017-09-22T15:46:29.692+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/neuroscience/engaging-patients-to-advance-research-in-alzheimers-disease09112017.html 2017-11-13T07:56:48.275Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/hot-topics.html 2016-01-19T16:29:09.054Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/uncategorized.html 2016-11-23T14:19:40.580Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/uncategorized/rejecting-the-one-size-fits-all-approach-the-early-science-behind-respiratory-biologics.html 2017-09-07T14:35:43.405+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/uncategorized/how-has-drug-discovery-developed-in-a-decade150917.html 2017-09-20T12:53:23.942+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/uncategorized/digital-technologies-revolutionizing-health-care-and-drug-development.html 2017-10-02T19:43:04.150+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/uncategorized/supporting-scientific-literacy-online-at-the-asco-annual-meeting-2018.html 2018-05-30T17:38:24.673+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors.html 2016-01-28T10:24:07.902Z https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/ajay-gautam.html 2017-07-06T14:28:57.362+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/alan-cross.html 2017-07-06T14:28:57.454+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/alec-van-gelder.html 2017-07-06T14:28:57.427+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/alison-holt.html 2017-07-06T14:28:57.414+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/anders-ekblom.html 2017-07-06T14:28:57.391+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/bahija-jallal.html 2017-07-06T14:28:57.398+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/barbara-slusher-ph-d-mas.html 2017-07-06T14:28:57.359+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/scott-baumgartner.html 2017-07-06T14:28:57.389+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/briggs-morrison.html 2017-07-06T14:28:57.406+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/carina-karrman-mardh.html 2017-07-06T14:28:57.369+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/helen-jackson.html 2017-07-06T14:28:57.435+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/j-carl-barrett.html 2017-07-06T14:28:57.382+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/carl-goodyear.html 2017-07-06T14:28:57.384+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/caroline-truman.html 2017-07-06T14:28:57.398+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/chris-yochim.html 2017-07-06T14:28:57.355+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/christopher-mccrae.html 2017-07-06T14:28:57.358+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/rongchang-chen-md-phd.html 2017-07-06T14:28:57.418+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/daniel-m-davis.html 2017-07-06T14:28:57.419+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/darren-cross.html 2017-07-06T14:28:57.387+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/detlev-biniszkiewicz.html 2017-07-06T14:28:57.378+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/don-frail.html 2017-07-06T14:28:57.361+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/dr-anneli-nordqvist.html 2017-07-06T14:28:57.351+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/dr-asud-khaliq.html 2017-07-06T14:28:57.409+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/dr-david-andrews.html 2017-07-06T14:28:57.369+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/dr-matthew-peters-m-d.html 2017-07-06T14:28:57.389+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/dr-magnus-johansson.html 2017-07-06T14:28:57.433+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/lauren-drowley.html 2017-07-06T14:28:57.443+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/alleyn-plowright.html 2017-07-06T14:28:57.363+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/emma-louise-jenkins.html 2017-07-06T14:28:57.348+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/dr-fiona-marshall.html 2017-07-06T14:28:57.421+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/flavia-borellini.html 2017-07-06T14:28:57.392+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/dr-gary-k-owens.html 2017-07-06T14:28:57.379+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/peter-akerblad-ph-d.html 2017-07-06T14:28:57.409+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/maarten-kraan.html 2017-07-06T14:28:57.467+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/graeme-robb.html 2017-07-06T14:28:57.429+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/graeme-wilkinson.html 2017-07-06T14:28:57.366+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/greg-rossi.html 2017-07-06T14:28:57.356+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/hans-denison.html 2017-07-06T14:28:57.376+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/harriet-fear.html 2017-07-06T14:28:57.377+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/hasan-jafri.html 2017-07-06T14:28:57.406+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/iain-patrick-chessell-ph-d.html 2017-07-06T14:28:57.363+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/jane-osbourn-ph-d.html 2017-07-06T14:28:57.435+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/jim-lynch.html 2017-07-06T14:28:57.453+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/joe-mather.html 2017-07-06T14:28:57.460+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/johan-jirholt.html 2017-07-06T14:28:57.388+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/thomas-hansson.html 2017-07-06T14:28:57.426+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/john-hennessey.html 2017-07-06T14:28:57.445+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/john-rex.html 2017-07-06T14:28:57.367+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/jonas-bostrom.html 2017-07-06T14:28:57.422+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/karol-sikora.html 2017-07-06T14:28:57.438+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/ken-grime.html 2017-07-06T14:28:57.391+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/ramon-hendrickx.html 2017-07-06T14:28:57.354+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/kevin-webster.html 2017-07-06T14:28:57.361+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/kirsty-rich.html 2017-07-06T14:28:57.430+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/krisna-nayak.html 2017-07-06T14:28:57.472+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/li-ming-gan.html 2017-07-06T14:28:57.435+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/lorraine-webber.html 2017-07-06T14:28:57.362+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/louis-diorazio.html 2017-07-06T14:28:57.369+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/marc-ditmarsch-md.html 2017-07-06T14:28:57.375+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/marcus-schindler.html 2017-07-06T14:28:57.354+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/dr-mark-e-duggan.html 2017-07-06T14:28:57.363+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/mark-wigglesworth.html 2017-07-06T14:28:57.381+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/matt-thomas.html 2017-07-06T14:28:57.386+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/matthew-sleeman.html 2017-07-06T14:28:57.440+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/menelas-pangalos.html 2017-07-06T14:28:57.472+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/mike-poole.html 2017-07-06T14:28:57.469+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/mike-waring.html 2017-07-06T14:28:57.361+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/mohammad-bohlooly.html 2017-07-06T14:28:57.468+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/paul-fleming.html 2017-07-06T14:28:57.431+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/paul-jansson.html 2017-07-06T14:28:57.383+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/naimish-patel.html 2017-07-06T14:28:57.409+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/manos-perros.html 2017-07-06T14:28:57.362+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/peter-held-md-phd-facc.html 2017-07-06T14:28:57.445+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/peter-honig.html 2017-07-06T14:28:57.403+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/peter-simpson.html 2017-07-06T14:28:57.448+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/peter-smethurst.html 2017-07-06T14:28:57.402+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/phil-jewsbury.html 2017-07-06T14:28:57.436+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/phillip-a-dennis.html 2017-07-06T14:28:57.414+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/prof-evgeny-n-imyanitov.html 2017-07-06T14:28:57.469+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/ramy-ibrahim.html 2017-07-06T14:28:57.397+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/ray-finlay.html 2017-07-06T14:28:57.393+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/mark-anderton.html 2017-07-06T14:28:57.408+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/regina-fritsche-danielsson.html 2017-07-06T14:28:57.450+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/richard-w-wagner-ph-d.html 2017-07-06T14:28:57.427+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/ross-stewart.html 2017-07-06T14:28:57.417+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/peter-le-souef.html 2017-07-06T14:28:57.407+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/rose-maciewicz.html 2017-07-06T14:28:57.457+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/ruth-march.html 2017-07-06T14:28:57.357+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/samantha-budd.html 2017-07-06T14:28:57.360+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/scott-butler.html 2017-07-06T14:28:57.447+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/scott-wilkins.html 2017-07-06T14:28:57.353+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/shalini-andersson-phd.html 2017-07-06T14:28:57.348+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/david-blakey-phd.html 2017-07-06T14:28:57.387+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/magnus-klarqvist.html 2017-07-06T14:28:57.347+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/shaun-grady.html 2017-07-06T14:28:57.420+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/stefan-platz.html 2017-07-06T14:28:57.388+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/stephen-zicha.html 2017-07-06T14:28:57.382+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/professor-steve-jackson.html 2017-07-06T14:28:57.374+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/steve-projan.html 2017-07-06T14:28:57.437+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/steve-yang.html 2017-07-06T14:28:57.459+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/sunita-desousa.html 2017-07-06T14:28:57.350+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/susan-galbraith.html 2018-03-28T09:33:05.590+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/tina-ryden-bergsten.html 2017-07-06T14:28:57.390+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/peter-greasley.html 2017-07-06T14:28:57.441+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/tomas-andersson.html 2017-07-06T14:28:57.402+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/tony-ho.html 2017-07-06T14:28:57.383+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/tracie-miles.html 2017-07-06T14:28:57.434+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/natalie-wilkinson.html 2017-07-06T14:28:57.428+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/vitali-proutski.html 2017-07-06T14:28:57.427+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/younghwa-kim.html 2017-07-06T14:28:57.434+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/elisabeth-bjork.html 2017-07-06T14:28:57.432+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/gunnar-olsson.html 2017-07-06T14:28:57.414+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/giovanni-melillo.html 2017-07-06T14:28:57.358+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/georgios-stratelis-md-ph-d.html 2017-07-06T14:28:57.465+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/craig-d-wegner-phd.html 2017-07-06T14:28:57.373+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/adam-smith.html 2017-07-06T14:28:57.459+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/chris-parker.html 2017-07-06T14:28:57.425+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/nancy-gillett.html 2017-07-06T14:28:57.445+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/martin-mackay.html 2017-07-06T14:28:57.426+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/christian-gardner.html 2017-07-06T14:28:57.471+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/stewart-owen.html 2017-07-06T14:28:57.427+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/sven-nylander.html 2017-07-06T14:28:57.438+01:00 https://www.astrazeneca.com/what-science-can-do/labtalk-blog/authors/christina-scherer.html 2017-07-06T14:28:57.399+01:00 https://www.astrazeneca.com/what-science-can-do/tlr-9.html 2017-09-29T10:23:18.833+01:00 https://www.astrazeneca.com/what-science-can-do/tlr-9/asthma-through-history.html 2016-02-12T14:41:23.273Z https://www.astrazeneca.com/what-science-can-do/osimertinib.html 2017-08-08T13:49:32.445+01:00 https://www.astrazeneca.com/what-science-can-do/ddr.html 2018-01-15T11:08:27.056Z https://www.astrazeneca.com/what-science-can-do/ddr/phc-tray-page-ngs.html 2017-12-08T11:38:00.898Z https://www.astrazeneca.com/what-science-can-do/ddr/phc-tray-page-mhi.html 2017-12-08T11:38:02.813Z https://www.astrazeneca.com/what-science-can-do/real-time-analytics-for-clinical-trials-react.html 2017-07-06T14:59:29.627+01:00 https://www.astrazeneca.com/what-science-can-do/single-molecule-detection-system1.html 2017-07-06T14:59:29.636+01:00 https://www.astrazeneca.com/what-science-can-do/cryoelectronic-microscope.html 2017-10-05T14:40:42.440+01:00 https://www.astrazeneca.com/our-science.html 2018-05-17T12:41:09.547+01:00 https://www.astrazeneca.com/our-science/pipeline.html 2018-05-17T12:41:25.079+01:00 https://www.astrazeneca.com/our-science/MedImmune.html 2017-09-08T11:19:09.129+01:00 https://www.astrazeneca.com/our-science/global-medicines-development.html 2017-07-06T12:48:42.591+01:00 https://www.astrazeneca.com/our-science/gothenburg.html 2018-02-23T10:38:02.227Z https://www.astrazeneca.com/our-science/cambridge.html 2018-05-02T10:58:52.062+01:00 https://www.astrazeneca.com/our-science/cambridge/our-community-involvement.html 2018-06-13T16:37:59.688+01:00 https://www.astrazeneca.com/our-science/cambridge/explore-cambridge.html 2018-05-02T11:17:07.972+01:00 https://www.astrazeneca.com/our-science/cambridge/astrazeneca-infographic.html 2018-05-14T16:49:30.347+01:00 https://www.astrazeneca.com/our-science/gaithersburg.html 2017-08-08T12:37:10.225+01:00 https://www.astrazeneca.com/our-science/publications.html 2018-06-11T11:57:02.400+01:00 https://www.astrazeneca.com/our-science/IMED.html 2018-05-31T10:54:50.896+01:00 https://www.astrazeneca.com/our-science/IMED/innovative-medicines-and-early-development-imed-biotech-unit-2017-a-year-in-review.html 2018-04-16T15:09:18.495+01:00 https://www.astrazeneca.com/our-focus-areas.html 2018-05-17T12:41:36.451+01:00 https://www.astrazeneca.com/our-focus-areas/cardiovascular-renal-and-metabolism.html 2018-06-05T09:49:04.590+01:00 https://www.astrazeneca.com/our-focus-areas/cardiovascular-renal-and-metabolism/heart-failure.html 2018-03-26T10:48:01.140+01:00 https://www.astrazeneca.com/our-focus-areas/cardiovascular-renal-and-metabolism/renal.html 2018-03-26T10:48:01.146+01:00 https://www.astrazeneca.com/our-focus-areas/cardiovascular-renal-and-metabolism/atherosclerosis.html 2017-08-25T16:40:10.942+01:00 https://www.astrazeneca.com/our-focus-areas/cardiovascular-renal-and-metabolism/diabetes.html 2017-08-25T16:43:17.587+01:00 https://www.astrazeneca.com/our-focus-areas/oncology.html 2018-06-19T17:56:53.673+01:00 https://www.astrazeneca.com/our-focus-areas/oncology/immuno-oncology.html 2018-04-04T06:53:14.438+01:00 https://www.astrazeneca.com/our-focus-areas/oncology/dna-damage-response.html 2018-04-05T18:56:44.780+01:00 https://www.astrazeneca.com/our-focus-areas/oncology/at-the-forefront-of-lung-cancer-treatment.html 2018-04-05T19:17:10.887+01:00 https://www.astrazeneca.com/our-focus-areas/respiratory.html 2018-05-22T14:18:24.795+01:00 https://www.astrazeneca.com/our-focus-areas/inflammation-and-autoimmunity.html 2017-11-30T19:43:47.396Z https://www.astrazeneca.com/our-focus-areas/inflammation-and-autoimmunity/my-journey-with-lupus-15032017.html 2017-07-06T12:48:42.583+01:00 https://www.astrazeneca.com/our-focus-areas/infection-and-vaccines.html 2018-02-22T11:44:41.788Z https://www.astrazeneca.com/our-focus-areas/neuroscience.html 2018-02-22T11:45:22.636Z https://www.astrazeneca.com/our-focus-areas/medicines.html 2018-04-24T10:59:18.568+01:00 https://www.astrazeneca.com/our-focus-areas/pearl-therapeutics.html 2018-04-16T17:18:50.768+01:00 https://www.astrazeneca.com/our-company.html 2018-06-12T09:58:08.966+01:00 https://www.astrazeneca.com/our-company/our-strategy.html 2018-05-18T07:37:48.951+01:00 https://www.astrazeneca.com/our-company/our-people.html 2018-06-07T11:54:58.281+01:00 https://www.astrazeneca.com/our-company/our-people/christopher-j-rhodes.html 2017-05-25T15:54:57.718+01:00 https://www.astrazeneca.com/our-company/our-people/nicolas-jose-guzman.html 2017-05-25T15:54:41.517+01:00 https://www.astrazeneca.com/our-company/our-people/helen-angell.html 2018-05-17T12:22:44.683+01:00 https://www.astrazeneca.com/our-company/our-people/david-wilson.html 2017-05-25T15:54:04.312+01:00 https://www.astrazeneca.com/our-company/our-people/jonathan-dry.html 2018-03-28T09:14:19.341+01:00 https://www.astrazeneca.com/our-company/our-people/ruth-march.html 2018-03-26T14:12:15.037+01:00 https://www.astrazeneca.com/our-company/our-people/mark-o-connor.html 2018-03-26T14:17:12.019+01:00 https://www.astrazeneca.com/our-company/our-people/regina-fritsche-danielson.html 2018-03-28T09:30:09.312+01:00 https://www.astrazeneca.com/our-company/our-people/stephen-delaney.html 2018-03-26T13:59:43.205+01:00 https://www.astrazeneca.com/our-company/our-people/benoit-destenaves.html 2017-07-06T14:59:29.613+01:00 https://www.astrazeneca.com/our-company/our-people/david-keeling.html 2018-03-28T09:28:01.496+01:00 https://www.astrazeneca.com/our-company/our-people/maria-groves.html 2017-05-25T15:51:14.026+01:00 https://www.astrazeneca.com/our-company/our-people/william-dall-acqua.html 2017-07-06T14:59:29.634+01:00 https://www.astrazeneca.com/our-company/our-people/herren-wu.html 2017-07-06T14:59:29.620+01:00 https://www.astrazeneca.com/our-company/our-people/kumar-srinivasan.html 2018-03-26T14:18:23.062+01:00 https://www.astrazeneca.com/our-company/our-people/shaun-grady.html 2017-05-25T15:49:46.141+01:00 https://www.astrazeneca.com/our-company/our-people/menelas-pangalos.html 2017-05-25T15:49:30.516+01:00 https://www.astrazeneca.com/our-company/our-people/bahija-jallal.html 2017-11-20T16:05:52.326Z https://www.astrazeneca.com/our-company/our-people/jane-osbourn.html 2017-05-25T15:48:52.639+01:00 https://www.astrazeneca.com/our-company/our-people/mark-fielding.html 2018-05-15T08:00:07.503+01:00 https://www.astrazeneca.com/our-company/our-people/li-ming-gan.html 2018-03-26T14:13:33.985+01:00 https://www.astrazeneca.com/our-company/our-people/biljana-naumovic.html 2017-05-25T15:45:08.731+01:00 https://www.astrazeneca.com/our-company/our-people/margareta-ozolins.html 2017-05-25T15:44:43.590+01:00 https://www.astrazeneca.com/our-company/our-people/paul-harper.html 2017-04-25T12:12:40.921+01:00 https://www.astrazeneca.com/our-company/our-people/Anthony-Johnson.html 2017-04-21T18:24:06.664+01:00 https://www.astrazeneca.com/our-company/our-people/donal-landers.html 2017-04-21T18:24:06.679+01:00 https://www.astrazeneca.com/our-company/our-people/roland-kolbeck.html 2017-05-17T16:43:23.626+01:00 https://www.astrazeneca.com/our-company/our-people/koustubh-ranade.html 2017-06-02T11:14:37.604+01:00 https://www.astrazeneca.com/our-company/our-people/katerina-pardali.html 2018-03-26T13:56:40.394+01:00 https://www.astrazeneca.com/our-company/our-people/emma-dean.html 2018-03-26T14:21:45.387+01:00 https://www.astrazeneca.com/our-company/our-people/amy-taylor.html 2018-03-26T14:22:41.803+01:00 https://www.astrazeneca.com/our-company/our-people/slave-petrovski.html 2017-12-14T18:56:59.185Z https://www.astrazeneca.com/our-company/our-people/leila-khoja.html 2017-11-20T19:42:27.062Z https://www.astrazeneca.com/our-company/our-people/maria-belvisi.html 2018-05-18T07:43:55.545+01:00 https://www.astrazeneca.com/our-company/our-people/ella-ekholm.html 2018-05-10T15:21:52.116+01:00 https://www.astrazeneca.com/our-company/our-people/ramon-nogueras.html 2018-05-10T13:13:57.152+01:00 https://www.astrazeneca.com/our-company/our-people/per-lindblom.html 2018-05-10T16:31:49.844+01:00 https://www.astrazeneca.com/our-company/our-people/elisa-lazaro-ibanez.html 2018-05-10T16:33:01.460+01:00 https://www.astrazeneca.com/our-company/our-people/rene-van-der-merwe.html 2018-05-21T09:19:53.503+01:00 https://www.astrazeneca.com/our-company/our-people/tom-keith-roach.html 2018-05-20T18:50:39.690+01:00 https://www.astrazeneca.com/our-company/our-people/colin-reisner.html 2018-05-18T07:39:29.082+01:00 https://www.astrazeneca.com/our-company/our-people/ralph-knoll.html 2018-06-07T11:54:25.413+01:00 https://www.astrazeneca.com/our-company/our-people/david-berman.html 2018-05-31T15:04:02.368+01:00 https://www.astrazeneca.com/our-company/leadership.html 2018-06-07T19:00:17.688+01:00 https://www.astrazeneca.com/our-company/leadership/pascal-soriot.html 2017-01-23T12:41:45.346Z https://www.astrazeneca.com/our-company/leadership/marc-dunoyer.html 2018-06-07T12:36:21.791+01:00 https://www.astrazeneca.com/our-company/leadership/marcus-wallenberg.html 2017-01-23T12:48:38.991Z https://www.astrazeneca.com/our-company/leadership/rudy-markham.html 2018-03-29T12:15:56.531+01:00 https://www.astrazeneca.com/our-company/leadership/baroness-shriti-vadera.html 2017-01-23T12:48:05.647Z https://www.astrazeneca.com/our-company/leadership/genevieve-berger.html 2018-03-29T12:17:31.762+01:00 https://www.astrazeneca.com/our-company/leadership/graham-chipchase.html 2017-01-30T16:20:15.964Z https://www.astrazeneca.com/our-company/leadership/jeff-pott.html 2016-03-08T14:41:52.687Z https://www.astrazeneca.com/our-company/leadership/menelas-pengalos.html 2016-08-23T15:51:39.635+01:00 https://www.astrazeneca.com/our-company/leadership/katarina-ageborg.html 2016-03-08T14:43:49.520Z https://www.astrazeneca.com/our-company/leadership/pam-cheng.html 2016-09-20T16:31:32.591+01:00 https://www.astrazeneca.com/our-company/leadership/fiona-cicconi.html 2016-03-08T14:45:39.159Z https://www.astrazeneca.com/our-company/leadership/ruud-dobber.html 2016-08-23T15:49:06.801+01:00 https://www.astrazeneca.com/our-company/leadership/bahija-jallal.html 2017-11-20T14:52:38.011Z https://www.astrazeneca.com/our-company/leadership/mark-mallon.html 2017-04-28T11:08:24.202+01:00 https://www.astrazeneca.com/our-company/leadership/sean-bohen.html 2016-03-08T14:52:28.542Z https://www.astrazeneca.com/our-company/leadership/Leon-Wang.html 2017-04-28T11:09:46.099+01:00 https://www.astrazeneca.com/our-company/leadership/Leif-Johansson.html 2018-03-28T08:01:12.549+01:00 https://www.astrazeneca.com/our-company/leadership/philip-broadley.html 2017-04-28T11:25:51.220+01:00 https://www.astrazeneca.com/our-company/leadership/jamie-freedman.html 2017-06-22T13:14:32.854+01:00 https://www.astrazeneca.com/our-company/leadership/iskra-reic.html 2017-06-22T13:10:14.782+01:00 https://www.astrazeneca.com/our-company/leadership/nazneen-rahman.html 2017-07-06T14:01:16.378+01:00 https://www.astrazeneca.com/our-company/leadership/sheri-mccoy.html 2017-10-02T17:14:06.822+01:00 https://www.astrazeneca.com/our-company/leadership/david-fredrickson.html 2017-10-10T14:49:23.906+01:00 https://www.astrazeneca.com/our-company/leadership/deborah-disanzo.html 2017-12-01T16:19:13.268Z https://www.astrazeneca.com/our-company/contact-us.html 2017-01-09T09:26:01.223Z https://www.astrazeneca.com/our-company/uk-hr-policies.html 2018-05-24T17:40:37.161+01:00 https://www.astrazeneca.com/our-company/code-of-ethics-app.html 2017-09-19T14:36:38.549+01:00 https://www.astrazeneca.com/country-sites.html 2015-09-16T11:32:46.644+01:00 https://www.astrazeneca.com/country-sites/slovakia.html 2018-06-14T16:44:19.855+01:00 https://www.astrazeneca.com/country-sites/thailand.html 2017-07-06T12:02:24.901+01:00 https://www.astrazeneca.com/country-sites/georgia.html 2017-07-06T13:51:55.965+01:00 https://www.astrazeneca.com/country-sites/croatia.html 2018-04-10T08:24:21.633+01:00 https://www.astrazeneca.com/country-sites/south-africa.html 2018-02-13T18:42:15.788Z https://www.astrazeneca.com/country-sites/sub-saharan-africa.html 2018-02-22T11:03:35.959Z https://www.astrazeneca.com/country-sites/near-east.html 2017-10-18T09:52:00.541+01:00 https://www.astrazeneca.com/country-sites/venezuela_.html 2018-01-16T12:27:56.392Z https://www.astrazeneca.com/country-sites/argentina.html 2017-11-13T12:46:43.133Z https://www.astrazeneca.com/country-sites/austria.html 2018-06-22T13:44:03.070+01:00 https://www.astrazeneca.com/country-sites/belgium.html 2018-06-19T17:08:25.343+01:00 https://www.astrazeneca.com/country-sites/bulgaria.html 2016-09-20T10:07:47.895+01:00 https://www.astrazeneca.com/country-sites/chile.html 2018-04-04T06:15:27.788+01:00 https://www.astrazeneca.com/country-sites/colombia.html 2015-10-28T11:05:05.090Z https://www.astrazeneca.com/country-sites/egypt.html 2018-05-30T13:14:49.811+01:00 https://www.astrazeneca.com/country-sites/egypt/az-egypt-statement-30052018.html 2018-05-30T16:34:31.530+01:00 https://www.astrazeneca.com/country-sites/estonia.html 2018-05-31T11:25:23.817+01:00 https://www.astrazeneca.com/country-sites/greece.html 2018-06-20T09:34:12.798+01:00 https://www.astrazeneca.com/country-sites/gulf.html 2017-08-08T17:49:40.047+01:00 https://www.astrazeneca.com/country-sites/hong-kong.html 2015-10-28T12:17:12.561Z https://www.astrazeneca.com/country-sites/hungary.html 2018-06-12T14:06:52.330+01:00 https://www.astrazeneca.com/country-sites/india.html 2018-06-01T11:02:13.046+01:00 https://www.astrazeneca.com/country-sites/ireland.html 2017-08-17T18:24:28.016+01:00 https://www.astrazeneca.com/country-sites/latvia.html 2018-01-19T12:24:49.188Z https://www.astrazeneca.com/country-sites/levant.html 2015-10-07T13:29:28.222+01:00 https://www.astrazeneca.com/country-sites/lithuania.html 2017-09-11T16:18:10.289+01:00 https://www.astrazeneca.com/country-sites/luxembourg.html 2018-03-26T10:48:01.147+01:00 https://www.astrazeneca.com/country-sites/malaysia.html 2017-02-22T09:47:01.344Z https://www.astrazeneca.com/country-sites/mexico.html 2018-06-13T18:08:10.445+01:00 https://www.astrazeneca.com/country-sites/mexico/mas-informacion.html 2015-10-13T09:23:40.227+01:00 https://www.astrazeneca.com/country-sites/south-korea.html 2017-07-07T13:45:08.485+01:00 https://www.astrazeneca.com/country-sites/switzerland.html 2018-06-01T09:13:21.434+01:00 https://www.astrazeneca.com/country-sites/switzerland/products.html 2018-05-15T14:49:42.783+01:00 https://www.astrazeneca.com/country-sites/taiwan.html 2018-06-21T10:43:52.348+01:00 https://www.astrazeneca.com/country-sites/the-philippines.html 2017-09-27T13:15:57.261+01:00 https://www.astrazeneca.com/country-sites/saudi-arabia.html 2018-05-08T07:17:01.248+01:00 https://www.astrazeneca.com/country-sites/singapore.html 2017-03-31T09:18:25.055+01:00 https://www.astrazeneca.com/country-sites/kazakhstan.html 2016-12-09T08:42:11.733Z https://www.astrazeneca.com/country-sites/slovenia.html 2018-06-20T13:02:00.952+01:00 https://www.astrazeneca.com/legal-notice-and-terms-of-use.html 2018-03-26T11:22:12.194+01:00 https://www.astrazeneca.com/privacy-notice.html 2017-07-07T14:07:53.864+01:00 https://www.astrazeneca.com/cookies.html 2017-01-12T11:33:18.642Z https://www.astrazeneca.com/global.html 2015-08-18T11:07:53.662+01:00 https://www.astrazeneca.com/global/en.html 2015-09-03T12:33:45.833+01:00 https://www.astrazeneca.com/global/en/500.html 2015-09-21T17:42:07.149+01:00 https://www.astrazeneca.com/global/en/503.html 2015-09-21T17:42:07.150+01:00 https://www.astrazeneca.com/global/en/Resources.html 2018-03-26T10:48:01.142+01:00 https://www.astrazeneca.com/global/en/global.html 2018-05-25T15:08:09.628+01:00 https://www.astrazeneca.com/global/en/our-company.html 2015-09-03T14:42:19.561+01:00 https://www.astrazeneca.com/global/en/our-company/media.html 2015-09-03T14:42:27.320+01:00 https://www.astrazeneca.com/global/en/sitemap.html 2018-05-11T13:53:28.127+01:00 https://www.astrazeneca.com/global/en/404.html 2017-07-07T14:04:09.067+01:00 https://www.astrazeneca.com/global/en/AstraZeneca-Websites.html 2018-06-05T14:04:47.165+01:00 https://www.astrazeneca.com/search-results.html 2017-02-08T15:35:06.167Z https://www.astrazeneca.com/ESMO-2017.html 2018-05-11T13:54:53.977+01:00 https://www.astrazeneca.com/ESMO-2017/supporting-social-media-citizens-at-esmo-2017.html 2017-09-08T12:11:06.584+01:00 https://www.astrazeneca.com/ESMO-2017/representing-the-patient-with-social-media-at-esmo-2017.html 2017-09-08T12:10:44.105+01:00 https://www.astrazeneca.com/ESMO-2017/a-renaissance-in-lung-cancer-research-at-esmo-2017.html 2017-10-09T09:35:59.738+01:00 https://www.astrazeneca.com/ESMO-2017/advancing-treatment-selection-for-patients-with-hormone-receptor-positive-advanced-breast-cancer.html 2017-09-08T12:10:08.279+01:00 https://www.astrazeneca.com/ESMO-2017/cracking-the-code-collecting-data-to-inform-treatment-and-support-access-to-treatment.html 2017-09-08T13:23:20.378+01:00 https://www.astrazeneca.com/ADA-2018.html 2018-06-22T09:05:10.392+01:00